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USE OF HARD GELATIN CAPSULES AND SODIUM ALGINATES IN 
PERORAL PROLONGED-RELEASE FORMULATIONS 
Peep Veski. 1994, University of Helsinki (FIN), pp 44 
ISBN 951-45-6768-4 
During the last years much attention has been paid to research and development of 
prolonged-release formulations. Quite few studies have been published concerning 
the biopharmaceutical characteristics of hard gelatin capsules as single-unit systems 
containing a simple mixture of a drug and hydrophilic polymer. The main aim of 
the present study was to define the usability of sodium alginate to modify drug 
release from hard gelatin capsules and press-coated tablets recently developed in 
the Department of Pharmacy, University of Helsinki. 
Sparingly water-soluble Ibuprofen and highly water-soluble pseudoephedrine 
hydrochloride were used as model drugs. For simulation of the plug formation in 
dosator-type capsule filling machines a special equipment was also constructed. 
Altogether 14 different grades of sodium alginate by trade names of Manucol and 
Manugel were used. 
In vitro release of Ibuprofen was determined at pH 7.2 and that of pseudoephedrine 
hydrochloride at pH 1.2, 4.4. and 7.2. To study the mechanism by which sodium 
alginate control drug release the dissolution medium contained also 0.1% fuchsin. 
At predetermined times capsules were removed from the dissolution apparatus and 
cut in two. Penetration of the coloured solution was evaluated by visual inspection 
and photography. Single-dose cross-over bioavailability studies were carried out in 
young healthy volunteers. Drug plasma concentrations were determined by HPLC. 
Using different grades of sodium alginate as diluents in hard gelatin capsules it 
was possible to prepare prolonged-release products from which drug absorption 
can be controlled over a fairly wide range without any fall in the amount of drug 
absorbed. This system was better suitable for the sparingly water-soluble drug, 
Ibuprofen, than for the highly water-soluble drug, pseudoephedrine hydrochloride. 
At pH 1.2 from all grades of sodium alginate alginic acid precipitated and it 
formed a tight outermost layer, which acts as rate-limiting layer for diffusion of 
the drug. The second layer was gelatinous and smooth. At pH 7.2 the outermost 
layer consisted only of sodium alginate gel and its tightness depended on the 
viscosity grade and chemical character of the sodium alginate brand used. The plug 
formation had only a minimal effect on drug release from capsule formulations 
containing sodium alginates. Sodium alginates could also be utilized for controlling 
drug release from press-coated prolonged-release tablets, using different types and 
different amounts of sodium alginate in the coat of the tablet. 
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1. INTRODUCTION 
1.1. Prolonged-release drug preparations 
In the last two decades much research and development work has been devoted to 
prolonged-release drug formulations because they have many advantages over 
conventional immediate-release formulations. For example, they allow less frequent 
drug administration, high peak-plasma concentrations resulting systemic side 
effects can be avoided, local high drug concentrations in the gastrointestinal tract 
resulting local side effects can be avoided, and the reduced degree of fluctuation 
in drug plasma concentrations improves therapeutic response. All of these 
advantages improve patient compliance (Notari 1980). 
Prolonged-release dosage forms owe a subset of modified-release dosage forms. 
The nomenclature describing such formulations is confused. Words used to 
describe modification of release include controlled, sustained, slow, prolonged, 
retarded, extended, depot, timed, delayed and rate-controlled. Few years ago, 
American and European health authorities suggested standardization of 
nomenclature for such drug products. In the study reported here this suggestion has 
been adopted on the basis described below. 
STANDARDIZED NOMENCLATURE OF 
MODIFIED-RELEASE DOSAGE FORMS 
1. Prolonged-release dosage forms 
1.1. Slow-release dosage forms 
1.2. Extended-release dosage forms 
2. Delayed-release dosage forms 
Categorization of a drug product in a subgroup is based on pharmacokinetic 
parameters determined in bioavailability tests. Reference must be made to 
parameters relating to an immediate-release formulation containing the same drug 
substance (Table 1). 
Most prolonged-release drug products are intended for peroral administration. The 
main criteria for approval of a prolonged-release preparation are (1) that drug 
absorption must be predictable and consistent, (2) that fluctuations in drug plasma 
concentrations in the steady-state must be equal to but preferably, less than those 
following more frequent administration of an immediate-release formulation and 
(3) that the amounts of drug absorbed should be at least 75 - 80 % of amounts 
absorbed from an immediate-release formulation (Skelly 1989). 
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Table 1. Assignment of modified-release dosage forms to subgroups on the basis 
of pharmacokinetic parameters as compared with corresponding parameters for an 
immediate-release dosage form containing the same drug substance. t,ag = lag time 
until commencement of absorption, t^ = time to peak concentration, Cmax = Peak 
concentration, t* = half-life of elimination phase. 
Type t|ag t"", с tvi 
Slow release = > < = 
Extended-release = > < > 
Delayed-release > > — 
= equal to, < less than, > greater than corresponding parameter for immediate-
release dosage form. 
Many techniques for obtaining prolonged-release drug products have been 
described. They include use of drug derivatives of low solubility in water, leading 
to low dissolution rates. Salts, complexes or prodrugs may be less water-soluble 
than the parent drug. Dissolution rate can also be decreased by increasing particle 
size of a drug. Drug can also be bound to ion exchange resins (Sjögren 1985). 
Use of such chemical and physical means of prolonging drug release are not 
common in preparing prolonged-release peroral dosage forms. It is commoner to 
devise special dosage forms or use additives. Peroral prolonged-release 
formulations are usually categorized in one or other of two groups, namely ,(1) 
single-unit preparations and (2) multiple-unit (multiparticulate) preparations 
(Beckett 1985). A single-unit preparation acts in its entirety as a drug releasing 
system. A multiple-unit preparation consists of numerous small drug delivery 
systems. The drug-release profile of the product as a whole is a sum of the drug-
release profiles of the individual parts. 
Peroral prolonged-release drug products can be prepared e.g. by mixing a drug 
with a resin insoluble in water. The resulting powder mass is granulated and the 
granules filled into hard gelatin capsules (multiple-unit system) or compressed into 
tablets (single-unit system). The resin forms an insoluble matrix from which the 
drug is released by diffusion through pores. Waxy materials can be used instead of 
resins. The mechanism of drug release is then erosion of the wax matrix. 
Another way of preparing prolonged-release tablets is to coat the tablets with an 
insoluble semipermeable coat. Granules can be similarly coated with such of coat. 
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A multiparticulate product can be prepared accordingly (Lordi 1986). 
In recent years use of hydrophilic polymers in prolonged-release peroral drug 
products has been intensively studied. The commonest type of preparation 
containing a hydrophilic polymer such as hydroxypropylcellulose, 
hydroxypropylmethylcellulose (HPMC) and sodium carboxymethylcellulose 
(NaCMC) is a single-unit tablet (Lordi 1986). Drug release from a hydrophilic 
matrix can take place by diffusion through a gel layer formed around the matrix 
or by gradual erosion of the gel matrix (Alderman 1984). 
L2. Hard gelatin capsules 
The two-piece telescopic gelatin capsule, invented by James Murdock, was 
patented in the United Kingdom in 1865. It is a popular dosage form, especially in 
Central Europe and USA. Gelatin is prepared by hydrolytic treatment of animal 
collagen. Common sources of collagen are animal bones and pigskin. Hard gelatin 
capsules allow ready availability of any drug they contain, since few excipients 
and little pressure are required (van Hosteller 1986). 
Hard gelatin capsules can also be used in preparing modified-release dosage forms. 
One simple way of producing multiple-unit products is to fill coated granules or 
matrix pellets into capsule shells (Lordi 1986). Prolonged-release single-unit 
systems can be made by using hydrophilic polymers as diluents in capsules. Liquid 
or semisolid hydrophobic materials can be used instead of hydrophilic powders in 
filling capsules (Hunter et al. 1982; Marvola et al. 1988; Bodmeier et al. 1990). 
Although prolonged-release hydrophilic matrix tablets have been the subject of 
intensive research and development few reportes have been published on the 
biopharmaceutical characteristics of hard gelatin capsules containing simple 
mixtures of drug and hydrophilic polymer. Prolonged-release ibuprofen capsules 
have been prepared using NaCMC (Marvola et al. 1991; Ojantakanen et al. 1993a) 
and HPMC (Ojantakanen et al. 1993a) as diluents. Furosemide capsules containing 
HPMC have also been shown to behave as a prolonged-release product in dogs 
(Smal et al. 1994). Drug release rate from hard gelatin capsules containing HPMC 
as a diluent has been shown to be decreased (Jalil and Ferdous 1993). 
Hard gelatin capsules have also been used to prepare prolonged-release products 
known as hydrodynamically balanced or buoyant capsules (Ingani et al. 1987; Oth 
et al. 1992). Such capsules contain sodium bicarbonate, which leads to formation 
of gas bubbles in the gel of the polymer (e.g. HPMC)in the stomach. Hydrophilic 
matrix capsules as modified-release drug delivery systems are easy to prepare on 
both bench and industrial scales. 
3 
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On an industrial scale, hard gelatin capsules are most frequently filled by means 
of so-called dosator-type machines (Jones et al. 1988). These consist of a dosing 
tube inside which there is a spring-loaded piston. The tube is plunged, open end 
first, into a powder bed. Material rises up into the tube, as far as the piston, to 
form a plug of powder. This can be consolidated by applying a compressive force 
to the piston. The plug is then placed in a capsule. The compressive forces 
nowadays used in industrial-scale machines for plug formation range typically 
from 50 to 300 N, or 5 to 30 kg (Lerk et al. 1979; Botzolakis and Augsburger 
1984; Shah et al. 1986; Augsburger 1988). 
On a small scale, and in development phases and basic research, capsules are filled 
manually. Such filling does not involve the plug formation that occurs on an 
industrial scale. Plug formation can, however, change the disintegration and gel-
forming properties of the capsule contents. It is important to know whether plug 
formation affects prolonged-release formulations. One aim of the study reported 
here was to develop simple equipment for simulating plug formation in connection 
with capsule filling. 
1.3. Press-coated prolonged-release tablets 
During the last five years, a press-coated prolonged-release tablet has been 
developed in the Division of Biopharmaceutics and Pharmacokinetics, Department 
of Pharmacy, University of Helsinki, (Sirkiä et al. 1992). The tablets consist of a 
core and a coat. Both the core and the coat would contain the drug but only the 
coat contains a polymer controlling release of the drug. Such a tablet can easily be 
prepared using the well-known compression-coating technique. An international 
patent application concerning this invention has been filed (patent application 
PCT/FI 92/242). 
Drug release from such tablets can be modified to obtain zero-order kinetics or 
kinetics reflering a release rate increasing with time (Sirkiä et al. 1992). A drug 
release-rate increasing with time could be valuable in diseases having marked 
diurnal rhythms. In such diseases, therapeutic drug concentrations should vary 
during the day. Drug levels should be highest when symptoms are most severe. 
For example, in rheumatism, morning stiffness is common. In theory, maximum 
drug levels could be achieved in the morning if a formulation from which drug 
release increased with time were administered the previous evening. 
Factors affecting release rates and release profiles from press-coated tablets are 
amounts and viscosity grades of polymers used in the coat, and ratios of drug dose 
in core and coat Up to now, the only polymer that has been found to behave as 
predicted in the invention has been HPMC (Sirkiä et al. 1993). In the study 
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reported here, the behavion of sodium alginates in the new type of dosage form 
was therefore also examined. 
1.4. Sodium alginates 
Sodium alginates are hydrophilic polysaccharides produced from selected species 
of brown seaweeds. Structurally, they are linear copolymers containing two types 
of sugar residue: D-mannuronate (M) and L-guluronate (G). These occur in 
alginate molecules in three types of sequence: poly-M, poly-G and poly-MG 
(McDowell 1986). Sodium alginates have been used in the food industry for a long 
time. They have also been intensively studied as additives to solid and liquid drug 
products. 
In 1978 Klaudianos published a report of his attempts to prepare prolonged-release 
alginate tablets. Sodium alginate has subsequently been used for preparation of 
calcium-induced alginate gel beads (matrices) by means of which prolonged drug 
release can be achieved (Badwan et al. 1985; Yotsuyanagi et al. 1987; Segi et al. 
1989; Östberg and Graffner 1992; Mürata et al. 1993; Tateshita et al. 1993; 
Östberg et al. 1993). 
Use of sodium alginate as such, without formation of calcium alginate, has been 
unusual. Timmins et al. (1992) studied use of two grades of sodium alginate as a 
hydrophilic polymer in verapamil matrix tablets. Alginate-based prolonged-release 
theophylline tablets and suspensions have also been studied (Fu Lu et al. 1991; 
Zatz and Woodford 1987). Ojantakanen et al. (1993b) used sodium alginate in 
Ibuprofen capsules but drug absorption from the resulting formulation in man was 
not prolonged. This could have been because sodium alginate of too low a 
viscosity grade was used. Sodium alginate has also been used with sodium 
bicarbonate in buoyant capsules (Stockwell et al. 1986). 
It is common in scientific papers for the term sodium alginate to be used without 
further classification. However, there are many different types of sodium alginate 
on the market differing in chemical and physical characteristics such as molecular 
weight and particle size (McDowell 1986). In research work, attention must be 
paid to such properties. 
1.5. Ibuprofen 
Ibuprofen is a nonsteroidal anti-inflammatory drug that inhibits prostaglandin 
synthetase. Ibuprofen is used for relief of acute pain and for pain relief in chronic 
diseases such as rheumatoid arthritis and osteoarthritis (Kantor 1979). Chemically 
it is d, 1 -2-(4-isobutylphenyl)propionic acid a weak acid (pK, 4.8) (Ritschel 1992). 
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It is practically insoluble in water. At pH 2.0 its solubility is 22 mg'll, at pH 7.0 
2440 mg-11 (Herzfeldt and Kummel 1983). 
Ibuprofen is rapidly and completely absorbed after peroral administration. It has 
been shown to be absorbed throughout the gastrointestinal tract, from the stomach 
to the rectum (Wilson et al. 1989). It is therefore a good candidate for formulation 
a prolonged-release product. In studies with solutions for oral administration, peak 
plasma concentrations were achieved 0.5 to 0.7 hours after administration 
(Gillespie et al. 1982; Lockwood et al. 1983; Marvola et al. 1991). For 
conventional tablets and capsules values of 1.3 to 2.7 hours have been reported 
(Gillespie et al. 1982; Stead at al. 1983; Palva et al. 1985; Benvenuti et al. 1986; 
Regazzi et al. 1986; Dash et al. 1988; Karttunen et al. 1990; Vidgren et al. 1991). 
Elimination half-life of Ibuprofen has been found to range from 1.5 to 2 hours 
(Lockwood et al. 1983; Karttunen et al. 1990). A short elimination half-life results 
in wide fluctuations between steady state maximum and minimum concentrations 
(Ritschel 1992). In long-term therapy, fluctuations in the plasma concentration with 
high concentration peaks are common with drugs rapidly absorbed and eliminated. 
To avoid this, use of a prolonged-release product is appropriate. 
Prolonged-release Ibuprofen formulations have been prepared by filling coated 
pellets into hard gelatin capsules (Regazzi et al. 1986; Wilson et al. 1989). 
Marvola et al. (1991) prepared prolonged-release ibuprofen capsules using 
NaCMC, Ojantakanen et al. (1993a) used HPMC as a diluent Shah et al. (1989; 
1990) prepared bimodal release gel matrices and divisible tablets to extend the 
absorption of Ibuprofen. Matrix formulations containing hydrophilic and 
hydrophobic polymers have also been prepared (Malamataris and Ganderton 1991). 
1.6. Pseudoephedrine hydrochloride 
Pseudoephedrine [(+)-(1 S,2S)-2-methylamino-1 -phenylpropan-1 -ol] is a 
stereoisomer of epnednne. It is a sympathomimetic, usually used as a decongestant 
but also employed as an antiasthma drug. Pseudoephedrine has fewer central 
nervous system effects than ephedrine. Pseudoephedrine is readily absorbed from 
the gastrointestinal tract It is largely excreted unchanged in the urine, with an 
elimination half-life of 5 to 8 hours. An increase in urinary pH to 8 lengthens the 
elimination half-life up to 18 hours (Kuntzman et al. 1971; Yacobi et al. 1980- Lin 
et al. 1985; Martindale The Extra Pharmacopoeia 1989). 
Pseudoephedrine has a pK, value of 9.86 (Ritschel 1992) or 9.22 (Merck Index 
1983). The hydrochloride salt is freely soluble in water. Pseudoephedrine 
hydrochloride is usually administered via conventional dosage forms as 60 mg 
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three or four times daily. Prolonged-release formulations containing 120 mg of 
pseudoephedrine hydrochloride have been marketed (Wecker et al. 1987; Bodmeier 
et al. 1991). Such formulations are administered twice daily. In commercial 
preparations, pseudoephedrine is often combined with codeine or an antihistamine. 
4 
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2. AIMS OF STUDY 
The main aim of the study reported here was to determine whether sodium alginate 
could be used to modify drug release in formulations for peroral administration. 
Hard gelatin capsule formulations were studied first because they are easy to 
prepare on a small scale and industrially. Use of sodium alginate in a new type 
prolonged-release press-coated tablet developed in the Division of 
Biopharmaceutics and Pharmacokinetics, Department of Pharmacy, University of 
Helsinki was also studied. 
In detail, the aims of the study were: 
to determine the effects of the chemical and physical properties of 
different grades of sodium alginate on the pharmaceutical 
characteristics of products 
to determine the properties of formulations containing only a 
sparingly water-soluble drug (ibuprofen) of a highly water-soluble 
drug (pseudoephedrine hydrochloride) 
to determine the mechanism by which sodium alginate controls drug 
release from capsule formulations 
to establish whether there were any differences between capsules 
filled manually and capsules filled using equipment that simulates 
plug formation in capsule-filling machines 
to conduct bioavailability studies of selected formulations in man. 
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3. MATERIALS AND METHODS 
3.1. Sodium alginates 
The polymers used to modify drug release in the studies reported in papers П-V 
were sodium alginates. Fourteen grades of sodium alginate manufactured by Kelco 
Ltd, were used in the study reported in paper II. Particular, grades were then 
selected for further experiments (reported in papers Ш-V). The trade names and 
specifications (chemical structure, viscosity grade and particle size) of the 14 
grades are reported in paper II. More detailed information about these substances 
can be found in the booklet by McDowell (1986). 
3.2. Model drugs 
In the studies reported in papers I-IV ibuprofen manufactured by Orion-Farmos 
Pharmaceutical was used as a model drug. It met the specifications of the 
European Pharmacopoeia and was used as supplied. It was regarded as 
representative of drugs that are only sparingly soluble in water. 
Pseudoephedrine hydrochloride manufactured by Knoll AG was selected as 
representative of highly water soluble drugs (paper V). It met the specifications of 
the European Pharmacopoeia. 
3.3. Additives 
In the study reported in paper I the capsules contained, in addition to ibuprofen, 
microcrystalline cellulose (Emcocel 90M™, E Mendell), methylcellulose 
(Methocel A4C, Dow Chemicals), lactose (De Melkindustrie Veghel), com starch 
(Maydis amylum, Thibola DRM), and dicalcium phosphate dihydrate 
(Emcompress™, E. Mendell). 
The press-coated tablets described in paper IV contained, in addition to ibuprofen 
and sodium alginate, potassium carbonate (Carlo Erba), directly compressible 
lactose (Pharmatose DCL), polyvinylpyrrolidone (PVP) (Kollidon K25, Fluka), 
magnesium stearate (EP) and talc (EP). 
3.4. Preparation of capsule formulations 
Size 0 hard gelatin capsules (Posilock™, Elanco) were used for all formulation. 
Amounts of drug required were weighed out in graduated cylinders and the other 
ingredients added to produce material sufficient for batches of 25 or 100 capsules. 
Powder were mixed in mortars and dispensed into capsule shells manually, using 
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a Feton apparatus. 
The compositions (amounts of drugs and other ingredients) of each formulation are 
given in the original publications. 
3.5. Plug formation 
To simulate plug formation in dosator-type capsule filling machines special 
equipment was constructed (paper I, Fig. 1). A dosing tube from a mG2 filling 
machine was fixed to a plastic plate. The plate was placed on a digital balance. A 
piston from the same mG2 machine was fixed to a lever system that could move 
up and down with a static rod. 
Plugs were made from the contents of capsules filled manually as described in 
section 3.4. The powder content of one capsule was poured into the dosing tube. 
The lever was steadily pulled down and the compression force towards the powder 
bed measured via the digital balance. After compression, the dosing tube was 
removed from the plastic plate and the plug was loaded into the capsule body. 
The compression forces tested in the study reported in paper I were 10, 20 and 30 
kg. For capsules containing sodium alginate compression force of 30 kg was used. 
Results are reported only in this summary. 
With powder mixtures containing sodium alginate it was not possible to prepare 
firm plugs. Powder mixtures containing sodium alginate were therefore 
pregranulated. To prepare granules, powders were moistened with a 10% 
polyvinylpyrrolidone (Kollidon K25) solution. The solvent consisted of water and 
ethanol (1:1). The wetted powder was sieved through a 0.7 mm sieve and dried 
overnight at 35°C. 
3.6. Preparation of press-coated tablets 
Press-coated tablets each consisted of a core and a coat. Drug (100 mg of 
ibuprofen) was divided between core and coat in the ratio 2:1. Only the coat 
contained sodium alginate, intended to control drug release. Detailed compositions 
of all tablets studied are given in paper IV. 
Cores containing ibuprofen, potassium carbonate, lactose, magnesium stearate and 
talc were compressed in a Korsch EK-0 (Erweka Apparatebau) single-punch 
machine, using concave 7-mm punches. The compression force used was 10-12 
kN. 
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Compression coating was performed manually using the same Korsch single-punch 
machine equipped with 11-mm punches. Ibuprofen and sodium alginate were 
mixed in a mixer (Turbula AG) for 10 minutes. The powder mass was moistened 
with a 10% PVP-water-ethanol solution and sieved through a 0.7 mm sieve. The 
granules were dried overnight at 35°C. For tableting, the fraction 0.3-0.7 mm was 
used. Magnesium stearate and talc were added to the granules. Half of the granules 
for one tablet were weighed into the die and the core was placed on the granule 
bed. The rest of the granules were added to the die and the tablet was compressed 
manually, using a force of about 20 kN. 
3.7. Dissolution tests 
3.7.1. Dissolution of ibuprofen 
Dissolution of ibuprofen was determined using the rotating basket method 
(capsules, papers I and II) or the paddle method (tablets, paper IV), as described 
for ibuprofen tablets in USP XXII. The dissolution medium was phosphate buffer, 
pH 7.2 (900 ml at 37°C). The speed of rotation was 150 min 1 for capsules and 50 
min'1 for tablets. 
The dissolution apparatus (Dissolutest 07, Prolabo) was connected to a flow-
through spectrophotometer (Ultraspect II, LKB Biochrom Ltd) via a peristaltic 
pump (Watson-Marlow 503S, Smith and Nephew). Absorbances of dissolution 
medium in 2-mm flow-through cells at 221 nm were recorded automatically at 
regular intervals. The reference ceil contained solvent saturated with the grade of 
sodium alginate used in the formulation concerned. Measurements were monitored 
using a computer running tablet-dissolution software (TDS™, LKB Biochrom Ltd). 
Release data relating to alginate-based ibuprofen capsules were fitted to zero-order 
kinetics curves (II). 
3.7.2. Dissolution of pseudoephedrine hydrochloride 
Dissolution of pseudoephedrine hydrochloride from capsules (V) was determined 
using the USP rotating basket method. Solvents of three pH values were used, 
namely (1) pH 1.2 (0.1 moH"1 hydrochloric acid), (2) pH 4.4 (phosphate buffer) 
and (3) pH 7.2 (phosphate buffer). The volume of dissolution medium was 900 ml 
and the temperature of the dissolution apparatus (Sotax AT 7) 37°C. The speed of 
rotation was 150 min"1. Samples of 1 ml were taken manually at predetermined 
times. 
Drug concentrations in the samples were determined using the high-performance 
liquid chromatography (HPLC) method described in section 3.10.2. Determination 
5 
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of pseudoephedrine (Dowse et al. 1983). The volume of sample administered to 
the injector was 10 pi. No extraction of samples was needed. Goodness of fits of 
dissolution curves to first-order and square-root-of-time equations were tested 
using Minsq™ software (Mircomath). 
3.8. Penetration of dissolution medium into capsules 
Penetration of dissolution medium into capsules was studied with formulations 
containing pseudoephedrine hydrochloride (V). The test was analogous to the 
ordinary dissolution test but the dissolution medium contained 0.1% fuchsin (E. 
Merck), giving it a red colour. At predetermined times, capsules were removed 
from the dissolution apparatus and cut in two. Penetration of the coloured solution 
was evaluated by visual inspection and recorder by photography. 
This summary includes results relating to penetration of dissolution medium into 
capsules not included in the original publications. 
3.9. Bioavailability studies 
All bioavailability studies were carried out in young, healthy volunteers (III-V) 
who participated in randomized, single-dose, cross-over studies carried out in 
accordance with the recommendations of the Declaration of Helsinki (World 
Medical Assembly 1964) as revised in Tokyo (1975). The study protocols were 
approved by the Ethical Committee of the University of Tartu. 
One week before the study, participants underwent routine medical control. 
Volunteers were informed about possible risks and side-effects of the drug. Their 
written consent to participation in the study was obtained. All were non-smokers. 
None took any medicine during the study or one week before it. 
Each drug product was administered with 200 ml of water following an overnight 
fast of at least 10 hours. The dose of ibuprofen was 400 mg, that of 
pseudoephedrine hydrochloride 100 mg. A standard lunch was provided 3 hours 
after drug administration. The washout period was at least one week. Blood 
samples (10 ml) were collected from a forearm vein into heparinized tubes at 
predetermined times. Plasma was separated by centrifugation approximately 30 
minutes after collection, and stored at -20 °C until analysed. 
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3.10. Plasma assay 
3.10.1. Determination of ibuprofen 
Ibuprofen plasma concentrations were determined by means of HPLC, using a 
slightly modified version of the method described by Avgerinos and Hütt (1986). 
The system was equipped with a Waters Model 501 piston pump, a Waters Model 
717 Intelligent Sample Processor, a Waters Model 486 tunable Absorbance 
Detector operating at 222 nm and a Waters Model 820 Maxima Workstation 
(Waters Ltd). Sample separation was carried out on a pBondapak C18 reverse-phase 
column (3.9 X 300 mm). The guard column was an RCSS pBondapak C18. The 
mobile phase was acetonitrile and 0.1 M sodium acetate (35:65), the pH of which 
was adjusted to 6.2 with glacial acetic acid. All chemicals were of analytical or 
HPLC grades. The flow rate was 2 ml min"1. 
The standard curve was found to be linear over the concentration range 2-40 
mgi"1 (r > 0.99), and passed close to the origin. The accuracy and precision of the 
method were investigated as recommended by Shah et al. (1992) by analysing six 
plasma samples containing drug concentrations of 2.0 and 40.0 mg-1"1. Mean 
values were 2.33 mg-1'1 coefficient of variation (CV 3.8%) and 40.2 mG-1"1 (CV 
5.8%), respectively. The limit of quantitation was 2 mg-1"1. No interfering peaks 
were observed in plasma blanks. 
3.10.2. Determination of pseudoephedrine 
Pseudoephedrine concentrations were determined by HPLC, using a version of the 
method of Dowse et al. (1983) modified in relation to handling of plasma samples. 
One millilitre of plasma, 50 pi of a saturated solution of sodium carbonate and 100 
pi of 2 M sodium hydroxide solution were vortexed for 15 seconds. Four millilitres 
of diethyl ether were added and tube were vortexed for one minute and centrifuged 
for 5 minutes. Two millilitres of ether extract were transferred to a centrifuge tube 
containing 100 pi of 5% acetic acid. The mixture was vortexed for one minute and 
centrifuged for 5 minutes. The ether layer was reduced and the water layer 
transferred to a clean tube, from which 50 pi were taken for determination of drug 
levels. Each plasma sample was analysed in triplicate. Mean values were 
calculated. 
HPLC equipment (Waters Ltd.) was as described in section 3.10.1. (Determination 
of ibuprofen). The UV detector was operating at 220 nm. The mobile phase was 
prepared by mixing acetonitrile (200 ml) with a 0.005 M solution of sodium-1-
heptanesulfonate in water (800 ml) and adding 2 ml of 1 M hydrochloric acid. The 
flow rate was 1.3 ml min'1. 
20 
The standard curve was found to be linear over the concentration range 50-1000 
ngml'! and passed close to the origin. The linear coefficient of determination was 
0.993 or better. Accuracy and precision of the method were investigated by 
analysing six plasma samples of pseudoephedrine concentrations of 50 and 500 
ngml"1. Mean values were 45.4 ngml'1 (C.V. 18.3%) and 484 ngml1 (C.V. 
2.7%). The limit of quantitation was estimated to be 50 ng-ml"1. No interfering 
peaks were observed in plasma blanks. 
3.11. Pharmacokinetic parameters 
The pharmacokinetic parameters assessed using the Siphar™ program (Simed) 
were maximum plasma concentration (Cmax), time to peak concentration (t^), area 
under concentration-time curve from time 0 to infinity (AUC), half-life of 
elimination phase (t^) and mean residence time (MRT). Cm„ and t^ values were 
used as measured. AUC and MRT values were calculated by the trapezoidal 
method, without logarithmic transformation. The ratio C^/AUC was also 
calculated and used to evaluate of the rate of the absorption phase (Shall and Luus 
1992). 
Statistical analyses were carried out using Student's t-test and Student's paired t-
test. Values of t^ were analysed using the nonparametric tests of Wilcoxon and 
Mann-Whitney. 
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4. RESULTS AND DISCUSSION 
4.1. Effects of different grade of sodium alginate on pharmaceutical 
properties of formulations 
4.1.1. Sodium alginate as diluent in hard gelatin capsules (II) 
Fourteen grades of sodium alginate were studied. Six were of the Manugel series 
(rich in guluronic acid), 8 of the Manucol series (rich in mannuronic acid). 
Viscosity grades in the Manugel series varied from 75 to 500 mPa*s, in the 
Manucol series from 4 to 300 mPa-s. Some differences existed in particle size 
between the grades (in paper П, Table 1). The drug studied was ibuprofen. Three 
drug:diluent ratios were investigated (П, Table 1-2). 
Dissolution of ibuprofen from 42 formulations was studied at pH 7.2. Drug release 
from each formulation followed zero-order kinetics. Rate constants for Manugel-
based capsules varied from 5.8 to 19.4 %-h"1, for Manucol based capsules from 
8.0 to 57.5%-h"1. It was therefore concluded that release rates of ibuprofen can be 
altered markedly through choice of a sodium alginate with appropriate chemical 
and physical properties. Additional adjustment is possible by varying the 
drug:diluent ratio. The relationship between release rate constant (ко) and relative 
amount of sodium alginate in the capsule was approximately linear. 
As a rule, release of ibuprofen from Manugel-based capsules was slower than that 
from capsules containing the equivalent viscosity grade of Manucol. This is in 
accordance with findings relating to tablets of verapamil hydrochloride based on 
Manugel and Manucol (Timmins et al. 1992). Manugels have been reported to 
form more rigid gels when hydrated than Manucols (McDowell 1986). More rigid 
gels may be less prone to erosion and constitute more effective barriers to release 
of drugs by diffusion. 
Because the grades of Manugels and Manucols studied differed as regards 
viscosity grade, it was difficult to draw conclusions about effect of particle size 
alone. A tendency for drug release to be slower as particle size increased was 
evident with Manugel (П, Fig. 5). With Manucol, there was no correlation between 
drug release rate and particle size. 
Use of various grades of HPMC as diluents in ibuprofen capsules resulted in 
square-root-of-time release kinetics. With many grades of NaCMC fairly good fits 
with zero-order kinetics were obtained (Ojantakanen 1992). The release rates of 
ibuprofen found in the studies forming the subject of this dissertation were similar 
to those with NaCMC-based ibuprofen capsules but higher than those with HPMC 
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based capsules. Release of ibuprofen, a weak acid, is no doubt faster from sodium-
alginate- and NaCMC-based capsules because of the ionic natures of the 
polymers. Zero-order release of ibuprofen, desirable in prolonged-release drug 
products, would seem to be related to use of ionic, and sodium-containing 
polymers, e.g. sodium alginate and NaCMC. 
4.12. Sodium alginate in coats of press-coated tablet (IV) 
Sodium alginate was studied as an ingredient of press-coated prolonged-release 
tablets. Four grades of sodium alginate were investigated (Manugel GHB, Manugel 
DPB, Manucol LF and Manucol DM). Amounts of sodium alginate in coats were 
also varied. The model drug was ibuprofen. The pH of dissolution medium was 
7.2. 
In every case, the release profile was biphasic (IV, Fig. 1). In the initial phase, 
release rates increased with time. The second phase fitted best with zero-order 
kinetics (TV, Fig. 2). Release rates in the second phase were higher than in the 
initial phase. By selecting an appropriate grade of sodium alginate it was possible 
to delay commencement of the faster second phase by 2 to 7 hours. Such release 
profiles were in accordance with the goals set for the press-coated tablets. 
A rank-order correlation existed between viscosity grade of sodium alginate and 
mean curves for cumulative amounts of ibuprofen released. The higher the 
viscosity grade, the lower the release rate (IV, Fig. 1). There were no marked 
differences between curves for tablets containing Manucol DM (viscosity 250 
mPa-s) and tablets containing Manugel GHB (viscosity 75 mPa-s). Viscosity 
grade of sodium alginate is therefore not the only factor that affects drug release 
from the present kind of press-coated tablet. This finding is in agreement with 
findings relating to capsule formulations (section 4.1.1). 
Amount of sodium alginate in coats affected the overall release rate but not release 
profile (TV, Fig. 3). However, amount of sodium alginate had a smaller effect than 
that of viscosity grade of sodium alginate. 
It was concluded that drug release rate from press-coated tablets developed could 
be controlled by appropriate choise of grade of sodium alginate. In this respect, 
sodium alginate differed from NaCMC, which did not function as expected in the 
type of press-coated tablets studied (Sirkiä et al. 1993). However, using sodium 
alginate, it did not prove possible to prolong release of ibuprofen from the press-
coated tablets as much as with HPMC (Sirkiä et al. 1992; Sirkiä et al. 1994). 
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4.13. Effects of dissolution pH on properties of sodium alginate capsules (V) 
Effects of pH of dissolution medium were examined for capsule formulations 
containing pseudoephedrine hydrochloride, the aqueous solubility of which does 
not depend markedly on pH in the physiological range. The pH levels investigated 
were 1.2, 4.4 and 7.2. Sodium alginate grades studied were Manugel DPB, 
Manugel GHB, Manucol DM and Manucol LD. 
At pH 1.2, similar to that in the stomach, there were no differences between the 
formulations. At higher pH values, differences between formulations were minimal, 
especially at pH 7.2 (V, Fig. 1). When the capsules contained Manucol DM, 
Manugel GHB or Manugel DPB, release rates of pseudoephedrine hydrochloride 
were highest at pH 1.2 and lowest at pH 4.4., except for Manugel DPB at pH 7.2 
(V, Fig. 1). Capsules containing the alginate of lowest viscosity grade (Manucol 
LD) differed markedly in behaviour. Drug release was slowest at pH 1.2, highest 
at pH 7.2. 
Timmins et al. (1992) found that release rates of verapamil hydrochloride from 
sodium alginate matrix tablets were only partially dependent on pH of the 
dissolution medium. If matrices had been prepared from sodium alginate rich in 
mannuronic acid (Manucol DMF) dissolution medium pH (1.2 or 7.4) had no 
marked effect on dissolution rate. In contrast, if the alginate used was rich in 
guluronic acid (Manugel DMP), reduction in pH significantly increased release 
rates of verapamil hydrochloride. In the studies reported here dissolution of 
pseudoephedrine hydrochloride depended on pH with all grades of sodium alginate. 
With Manugel DPB, Manugel GHB and Manucol DM, dissolution rates were 
highest at pH 1.2. With Manucol LD dissolution rate was lowest at pH 1.2. 
Dissolution rates of pseudoephedrine, which is highly water soluable, were higher 
than those of ibuprofen, which is sparingly soluble in water, from similar capsules 
at pH 7.2 (П, V). 
min 
Fig. 1. Penetration of dye in solvent (pH 1.2) into pseudoephedrine hydrochloride 
capsules containing Manugel DPB as diluent. 
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Fig. 2. Penetration of dye in solvent (pH 1.2) into Ibuprofen capsules containing 
Manugel DPB as diluent. 
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Fig. 3. Penetration of dye in solvent (pH 7.2) into pseudoephedrine hydrochloride 
capsules containing Manugel DPB as diluent. 
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Fig. 4. Penetration of dye in solvent (pH 7.2) into Ibuprofen capsules containing 
Manugel DPB as diluent. 
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4.2. Penetration of dissolution medium into capsules 
To obtain more information on gel-formation and drug-release mechanisms, a dye 
(fuchsin) was added to dissolution media. Experiments were carried out at two pH 
levels (1.2 and 7.2) with Manugel-DPB-based formulations containing Ibuprofen 
or pseudoephedrine hydrochloride. 
Figure 1, showing findings with pseudoephedrine capsules at pH 1.2 is analogous 
to Figure 2 in original publication V. After 30 minutes three layers were visible, 
two wet and one dry. The outermost layer was thin, tight and fairly hard. The 
second layer was gelatinous and smooth. The intensity of red in this layer was 
greater than that in the outermost layer. The core of the capsule was dry. After one 
to 3 hours, three layers remained visible. The thickness of the outermost layer 
increased more rapidly than that of the second layer. Dry powder was only visible 
in photographs for up to 4 hours. After 6 hours the gelatinous layer had almost 
totally disappeared. 
Under similar conditions (pH 1.2), Ibuprofen capsules behaved similarly (Fig. 2). 
Three layers were visible but penetration of dye into the capsule was slower. 
Only two layers were observed in capsules when dissolution tests were carried out 
at pH 7.2. For up to 6 hours dry or partially wetted powder was surrounded with 
a gel layer. Initially this layer was thin and brittle. After one to 2 hours the gel 
around pseudoephedrine capsules was so weak that it was impossible to cut the 
capsules in two (Fig. 3). The gel layer became thicker with time. After 6 hours the 
gel was of maximum thickness. 
When capsules contained Ibuprofen and dissolution was studied at pH 7.2, 
penetration of dye was slower than with pseudoephedrine capsules (Fig. 4). It was 
difficult to cut capsules in two without breaking them, at all times. 
At pH 1.2 the volumes of the formulations did not increase, i.e. there was no 
swelling of sodium alginate. At pH 7.2. volumes of capsules increased. This was 
especially evident with pseudoephedrine capsules. 
In the dissolution tests at pH 1.2 the hydrochloric acid reacted with the sodium 
alginate, and the outermost layer consisted of precipitated alginic acid. The gelatin 
shell could also have played a role in commencement of formation of an outermost 
layer (Carstensen and Rhodes 1993 ). As the dissolution medium penetrated the 
capsule, hydrogen ions would have been exchanged for sodium ions, and the 
dissolution medium would have declined in acidity. A second gelatinous layer 
would therefore have formed only when a slightly acidic, i.e. almost neutral 
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solution, moistened the sodium alginate. This would explain why there was no 
difference in dissolution curves between formulations at pH 1.2 (V, Fig. 1.). In all 
formulations, alginic acid precipitated and formed a tight outermost layer that 
acted as a rate-limiting layer in relation to diffusion of drug. 
The differences between Ibuprofen and pseudoephedrine hydrochloride capsules 
observed in penetration studies at pH 1.2 may be explicable on the basis of 
differences in aqueous solubility and chemical natures of the two model drugs. At 
pH 7.2 alginic acid cannot precipitate. The outer layer consists only of sodium 
alginate gel.Its tightness depends on the viscosity grade and chemical nature of the 
sodium alginate used. 
4.3. Effect of plug formation on in vitro properties of pseudoephedrine 
hydrochloride capsules 
In the study described in paper I, simple equipment simulating plug formation in 
dosator-type capsule filling machines was constructed. With this simulator it was 
possible to measure the compression force used in plug formation. Plug formation 
using the simulator corresponded to plug formation in a real capsule-filling 
machines. In this respect, it was better than the simulators designed by Lerk et al. 
(1979), Joliiffe et al. (1982) or Naidoo (1989). 
The suitability of the simulator was tested by preparing Ibuprofen capsules 
containing typical diluents. Various compression forces were used. Drug 
dissolution was studied. Dissolution characteristics of capsules filled using the 
simulator were similar to those obtained when corresponding formulations filled 
using on mG2 filling machine (Hannula et al. 1989). 
With powder mixtures containing sodium alginate it was impossible to compress 
the plugs needed in dosator-type filling machines. A granulation was needed to 
allow preparation of sodium-alginate-based capsules. To determine of granulation 
affected drug release rate, capsules containing ungranulated and granulated powder 
mixtures were prepared, using pseudoephedrine as drug. There were no marked 
differences in drug-release curves between Manucol LD based capsules filled 
without compressipn force (Fig. 5). Differences in results at pH 1.2. and 7.2 were 
minimal. 
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Fig. 5. Effects of granulation and compaction on dissolution of pseudoephedrine 
hydrochloride from Manucol LD based capsules at pH 1.2 (upper panel) and at pH 
7.2 (lower panel). + = powder mixture, A = granules, • = granules with 
compression force of 30 kg. 
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Fig. 6. Effects of granulation and compaction on dissolution of pseudoephedrine 
hydrochloride from Manugel DPB based capsules at pH 1.2 (upper panel) and at 
pH 7.2 (lower panel). + = powder mixture, A = granules, • = granules with 
compression force of 30 kg. 
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When Manugel DPB was used small differences were seen between the granulated 
and the ungranulated formulations (Fig. 6). At pH 1.2 granulation increased the 
dissolution rate of pseudoephedrine hydrochloride slightly. At pH 7.2 the effect 
was the reserve. 
The effects of plug formation (compaction) are also shown in Figs. 5-6. It was 
concluded that there were no marked differences in release profiles of 
pseudoephedrine hydrochloride from capsules containing granules produced 
without compaction and granules compacted using a force of 30 kg. This was most 
evident with Manucol LD based capsules, less marked with Manugel DPB based 
capsules. This is a good characteristic for sodium alginate based capsules. Slight 
variations in compression force during filling would have no marked effects on the 
in vitro properties of the formulation. 
4.4. Bioavailability of sodium alginate based formulations 
4.4.1. Bioavailability of ibuprofen from hard gelatin capsules (III) 
On the basis of the results of the in vitro studies reported in paper II, four 
formulations were chosen for bioavailability studies in man, namely ibuprofen 
capsules based on Manucol LD, Manucol DM, Manugel GHB and Manugel DPB. 
Detailed results of the experiments are shown in Table I and in Figures 1-3 on 
paper Ш. 
When the lowest viscosity grade of sodium alginate (Manucol LD) was used as 
diluent, the absorption profile of ibuprofen (t^ 1.9 h, t^ 2.5 h) did not differ 
markedly from that for conventional ibuprofen preparations (Gillespie et al. 1982; 
Stead et al. 1983; Lockwood et al. 1983; Palva et al. 1985; Benvenuti et al. 1986; 
Regazzi et al. 1986; Dash et al. 1988; Karttunen et al. 1990). It was concluded that 
a very low viscosity grade sodium alginate such as Manucol LD did not markedly 
prolong the absorption of ibuprofen. 
The higher viscosity grades (Manucol DM, Manugel GHB and especially Manugel 
DPB) led to noticeable prolongation of drug absorption. Statistically significant 
differences were seen in relation to t^, CmK, C^/AUC and MRT values of 
capsules containing Manugels as compared to Manucol LD based capsules (Ш, 
Table П). The t^ of Manugel DPB capsules also differed significantly from that of 
Manucol LD capsules. Accordingly, ibuprofen capsules based on Manucol DM or 
Manugel GHB was classified as slow-release products, and capsules containing 
Manugel DPB were categorized as an extended-release product 
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The overall conclusion from the studies with ibuprofen capsules was that by using 
with different viscosity grades of sodium alginate it is possible to prepare capsules 
of a sparingly water-soluble drug such as ibuprofen the rate of absorption of which 
can be controlled over a fairly wide range without any decline in overall amount 
of drug absorbed. 
4.42. Bioavailability of ibuprofen from press-coated tablets (IV) 
In the next stage the suitability of sodium alginate was studied in press-coated 
modified-release tablets. The four grades of sodium alginate used were Manucol 
LF, Manucol DM, Manugel GHB and Manugel DPB. The sodium alginate was 
confined to the coat of the tablet. Detailed results are given in Figures 4-5 and 
Table 1 in paper IV. 
As far as extent of bioavailability of ibuprofen was concerned, no differences were 
found between the formulations. AUG values were of similar magnitudes to those 
obtained with corresponding immediate-release products. These findings consistent 
with those of many other investigations in which formulations factors have been 
found to have no marked effects on amounts of ibuprofen absorbed (Regazzi et al. 
1986; Marvola et al. 1991; Ojantakanen et al. 1993). 
The parameter that appeared to distinguish the formulations from each other best 
seemed to be the ratio CmM/AUC. This is in accordance with the opinion of Shall 
and Luus (1992). The absorption rate characteristics of tablets containing Manucol 
LF were similar to those of immediate-release ibuprofen products (t^ 2.7 h and 
tvj 2.3 h). Peak concentrations were seen in every volunteers. This finding is typical 
of immediate-release formulations. 
Tablets containing Manucol DM were classified as a slow- release formulation. 
They differed statistically significantly from Manucol LF tablets in terms of CmM, 
Qnax/AUC and t^ values. The pharmacokinetic profile of the Manugel GHB based 
tablets was very similar to that of the Manucol DM tablets, although the viscosity 
grade of Manugel GHB is 75 mPa-s and that of Manucol DM 250 mPa-s. 
Manugel DPB tablets were classed as an extended-release formulation, since the 
value was 4.3 hours, as compared with 1.6 hours for immediate-release products 
(Ojantakanen et al. 1993a). 
The main conclusion drawn from this part of the study was that by using sodium 
alginates of different chemical structures or viscosity grades it is possible to 
prepare press-coated ibuprofen tablets from which the absorption rate can be 
controlled over a fairly wide range, from an immediate-release formulation via 
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slow-release formulations to an extended-release product. The pharmacokinetic 
parameters of the Manucol and Manugel based tablets described are similar to 
those for hard gelatin capsules containing the same viscosity grades of sodium 
alginate (Ш). 
4.4.3. Bioavailability of pseudoephedrine hydrochloride from hard gelatin 
capsules (V) 
Bioavailability studies of sodium alginate based hard gelatin capsules containing 
the highly water-soluble drug pseudoephedrine hydrochloride were also conducted. 
Three grades of sodium alginate were used, Manucol LD, Manucol DM and 
Manugel DPB. The fourth formulation studied contained the drug only. 
When the lowest viscosity grade of sodium alginate (Manucol LD) was used, 
prolongation of absorption was relatively slight. The mean value of the 
reference product was 2.9 hours. For the Manucol LD based product the 
corresponding value was 4.0 hours. There were no significant differences in 
relation to MRT on Cmax/AUC values. 
When Manucol DM and Manugel DPB were used, absorption of pseudoephedrine 
was more retarded: t^ for both formulations was 6.5 hours. MRT and Cmax/AUC 
values also differed significantly from those for the reference product. Elimination 
half-lives (t^) for the reference capsule and capsules containing sodium alginates 
were not significantly different. Manucol DM and Manugel DPB formulations 
were classified as slow-release preparations. In studies with ibuprofen, use of 
Manugel DPB led to extended-release formulations (Ш and IV). 
The overall conclusion from this part of study was that prolonged-release 
formulations containing sodium alginate are better in relation to drugs sparingly 
soluble in water than in relation to highly water-soluble drugs. However, Manugel 
DPB based pseudoephedrine capsules are competitive, as far as biopharmaceutical 
characteristics are concerned with commercial prolonged-release pseudoephedrine 
tablets (Wecker et al. 1987). 
4.5. Comparison of in vitro and in vivo results 
With ibuprofen capsules, a fairly good correlation was found between in vitro and 
in vivo results. The best linear correlation was found between the ratio Cmax/AUC 
and the zero-order rate constant (III, Fig. 4) (correlation coefficient 0.999). 
Between Cmix and ky the correlation coefficient was 0.997). With the other rate 
parameters, t^ and MRT, not even a rank-order correlation was found. 
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A fairly good in vitro/in vivo correlation was found with the press-coated 
ibuprofen tablets (IV). A rank-order correlation existed between cumulative 
dissolution curves and pharmacokinetic rate parameters. The similarity between 
formulations containing Manucol DM and Manugel GHB was evident in both in 
vitro results (IV, Fig. 1) and absorption curves (IV, Fig. 5). 
With the pseudoephedrine hydrochloride capsules drug release from sodium 
alginate capsules was studied of in solutions different pH levels (V). Results of in 
vitro studies in acid environments, e.g. at pH 1.2, are often said to allow optimum 
prediction of the in vivo fate of a drug product. In the study reported in paper V 
there were no differences between the four formulations at pH 1.2. However, in 
vivo differences between the formulations were fairly marked. 
It is possible that the capsules remained for 0.5 to 2 hours in the stomachs of 
volunteers. During this time, an outer layer of precipitated alginic acid would have 
been formed. A similar layer was seen in in vitro studies (V, Fig. 2). The alginic 
acid layer, which is not hydrophilic, does not favour adherence of an formulation 
to the gastric mucosa for long periods. Under fasting conditions, the "housekeeper 
wave" appearing approximately every second hour (Minami and McCallum 1984), 
would have swept the capsule to the small intestine. The solution that would then 
have penetrated the capsule would no longer have been acid. The rest of the 
sodium alginate in the capsule would have formed a gel the tightness of which 
depended on the viscosity grade of the polymer. This may have been why the in 
vivo absorption rate correlated with the viscosity grade of the sodium alginate used 
although no differences were seen in dissolution studies at pH 1.2. 
The results of the studies reported here confirm that although results of in vitro 
studies often allow prediction of in vivo behaviour of a drug product for oral 
administration there are cases where no in vitro/in vivo correlation exists. 
Biopharmaceutical evaluation of new formulations are therefore important from the 
onset. 
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5. CONCLUSIONS 
On the basis of the present results reported the following conclusions can be 
drawn: 
1. Using sodium alginate as a diluent in hard gelatin capsules prolonged-release 
drug profucts for oral administration can be prepared from which drug absorption 
can be controlled over a fairly wide range without any reduction in overall amount 
of drug absorbed. To adjust drug release rate and absorption rate, different 
viscosity grades of sodium alginate, different chemical types of sodium alginate 
and different drug/polymer ratios can be used. 
2. Sodium alginate based capsules function adequately as a drug delivery system 
for highly water-soluble drugs (e.g. pseudoephedrine hydrochloride) and sparingly 
water-soluble drugs (e.g. ibuprofen). However, the system is better for sparingly 
soluble drugs such as ibuprofen. 
3. Drug release from sodium alginate capsules is based both on drug diffusion 
though the gel layer formed around the capsule and on erosion of this gel layer. 
The durability and tightness of the gel depends on the viscosity grade and amount 
of sodium alginate used. At pH 1.2, however, alginic acid is precipitated with all 
grades of sodium alginate. This would explain why there were no differences in 
dissolution properties at pH 1.2 between formulations containing different grades 
of sodium alginate. 
4. Plug formation, which is usually an essential part of capsule-filling procedures 
on an industrial scale, had only minimal effects on drug dissolution from sodium 
alginate based capsules. It may therefore be assumed that results obtained with 
capsules filled manually predict the characteristics of corresponding formulations 
filled by means of dosator-type filling machines. 
5. Sodium alginate can be used to control drug release from a new type of press-
coated prolonged-release tablet. By using different types and different amounts of 
sodium alginate in the coat of the tablet it is possible to adjust drug absorption 
rates without declines in overall amounts of drug absorbed. 
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Abstract 
In the study reported, simple equipment was constructed to allow plug forma­
tion and compression force measurement, simulating dosator type capsule filling 
machines. A piston was removed from an industrial-scale filling machine and fixed 
to a lever system which could move up and down. A dosing tube was also remo­
ved and fixed to a plastic plate on a digital balance. The compression force during 
formation was recorded via the balance. 
7e equipment was used to prepare ibuprofen capsules containing typical 
diluents. Various compression forces were tested. Dissolution of ibuprofen from 
the formulation was tested using USP XXII the rotating disk method. The results 
showed that the dissolution properties of the formulations studied were similar to 
those previously demonstared for analogous capsule formulations. It was conc­
luded that the equipment described may therefore be used in basic research on 
hard gelatin capsule formulations. 
Tiivistelmä 
laisia puristeita, joita jauheseoksesta syntyy mäntäannostin-tyyppisessä kapse-
lientäyttökoneessa, ja samalla pystyttiin mittaamaan myöspuristeen muodostami-
sessa käytetty voima. Kaupallisesta kapselien täyttölaitteesta irroitettiin mäntäja 
kiinnitettiin ylös ja alas liikkuvaan vivustoon. Myös annostussylinteri irroitettiin ja 
kiinnitettiin muovilevyyn, joka asetettiin ylätasovaa'alle. Puristava voima luettiin 
vaa'an asteikolta. 
Konstruoidulla laitteella valmistettiin ibuprofeenia ja tyypillisiä täyteaineita sisäl-
täviä kapseleja käyttäen eri suuria puristavia voimia. Ibuprofeenin liukeneminen 
valmisteista tutkittiin USP:n pyrivä kori-menetelmällä. Tuloksetosoittivat, että nyt 
valmistettujen kapselien dissoluutio-ominaisuudet olivat samanlaiset kuin mitä 
aikaisemmin on kuvattu vastaaville koneellisesti täytetyille formulaatioille. Näin 
ollen nytesitettyä laitetta voidaan käyttää kovien liivatekapselivalmisteiden perus-
tutkimuksessa. 
plug formation 
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Introduction 
Hard gelatin capsules are suitable for both manual and industrial-scale 
preparation of drug products. Typically, the only additive required is a diluent. For 
industrial-scale filling machines, a glidant or lubricant is also required. Nowadays, 
most commercially available capsules are filled by compressing a powder to a 
plug and loading it into the capsule body. The compression forces used typically 
range from 50 to 300 N (5 to 30 kg) (LERK etat. 1979, BOTZOLAKIS and AUGSBURGER 
1984, SHAH et al. 1986, AUGSBURGER 1988). 
Compression force can be measured during manufacture on industrial-scale 
machines if these are equipped with appropriate measuring instruments. 
Instrumented filling-machine simulators have also been designed (JOLLIFFE et al. 
1982). Such equipments are, however, expensive, and not available in every 
laboratory. 
On laboratory scale, instrumented single-punch tableting machines have been 
used to prepare plugs for capsule filling procedures (NAIDOO 1989). Special die 
and plunger assemblies, in which the plunger is connected to a load cell have 
been constructed for preparation of plugs (LERK et al. 1979). Plug formation in the 
above-mentioned equipment does not however correspond accurately to plug 
formation in capsulefilling machines. 
The aim of the study reported here was to develop simple equipment for 
simulating plug formation in connection with capsule filling and measurement of 
compression force simply enough to allow it to be undertaken in basic research 
laboratories. The suitability of the assembly for its intended purpose was tested 
by preparing ibuprofen capsules containing typical diluents using different 
compression forces and studying the dissolution characteristics of the resulting 
formulations. 
Material and Methods 
E q u i p m e n t  f o r  p l u g  f o r m a t i o n  
The equipment constructed is shown in Fig. 1. A dosing tube from a mG2 dosator-type capsule 
filling machine was fixed to a plastic plate. The plate was placed on a digital balance (max. capacity 
30 kg). A piston from the same mG2 capsule filling machine was fixed to a lever system which could 
move up and down a static rod. 
Powder sufficient for one capsule was poured into the dosing tube. The lever was steadily pulled 
down and the compression force towards the powder bed was measured via the digital balance. 
After compression, the dosing tube was removed from the plastic plate and the plug was loaded into 
the capsule body. 
C a p s u l e  f o r m u l a t i o n s  
Size 0 hard gelatin capsules (Posilock™, Elanco) were used in the formulations. As a model drug 
ibuprofen (Medipolar) was used. The diluents tested were microcrystalline cellulose (Emcocel 90 
M™, E. Mendell), methylcellulose (Methocel A4C, Dow Chemicals), lactose (De Melkindustrie 
Veghel), corn starch (Maydis amylum, Thibola DRM), dicalcium phosphate dihydrate (Emcom-
press™, E. Mendell). The amounts of ibuprofen and the diluents in the formulations are shown in 
Table I. 
The necessary amounts of drug substance were weighed out in a graduated cylinder and diluent 
was added in sufficient quantity material for a batch of 100 capsules (68 ml). The powder was mixed 
manually and the capsule shells were filled using a Feton apparatus. These capsules were regarded 
as having been prepared using a compression force of 0 kg. The required number of capsules from 
each batch were then opened and the contents poured into the dosing tube. Plugs were then 
compressed using forces of 10, 20 or 30 kg. 
D i s s o l u t i o n  t e s t  
Dissolution of ibuprofen was determined using the USP rotating basket method as described for 
dissolution of ibuprofen tablets in USP XXII (Dissolutest™, Prolabo). The dissolution medium was 
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Flg. 1. A schematic diagram of the equipment used for plug formation and measurement of 
compression force; 1. dosing tube, 2. piston, 3. balance, 4. lever, 5. spring, and 
6. static rod. 
phosphate buffer pH 7.2 (900 ml at 37 °C) and the rotating speed 150 min1. The dissolution apparatus 
was connected via a peristaltic pump (Watson-Marlow 503S, Smith & Nephew) to a flow-through 
spectrophotometer (Ultrospec II, LKB Biochrom Ltd). The pump was operated at a delivery rate of 
7 ml • min1. The absorbance of the dissolution medium in 2 mm flow-through cells was recorded at 
221 nm, automatically, at regular intervals. Measurement was controlled by a computer running 
tablet-dissolution sofware (TDS™, LKB Biochrom Ltd). 
Table I Formulations studied. 
Amount of Amount of 
Diluent diluent ibuprofen 
mg mg 
Microcrystalline cellulose 100 200 
Microcrystalline cellusose 200 100 
Microcrystalline cellulose 250 50 
Methylcellulose 155 200 
Methylcellulose 255 100 
Methylcellulose 305 50 
Calcium phosphate 300 200 
Calcium phosphate 400 100 
Calcium phopshate 450 50 
Lactose 195 200 
Lactose 380 100 
Lactose 435 50 
Corn starch 200 200 
Results 
The dissolution profiles of ibuprofen capsules (200 mg) filled manually without 
compression are shown in Fig. 2. The diluent had very little effect on the 
dissolution rate of the drug. Dissolution was most rapid from capsules containing 
calcium phosphate and slowest from capsules containing methylcellulose. 
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Flg. 2. Dissolution of ibuprofen from capsules containing various diluents and200 mg of ibuprofen 
(no compression). Diluents: calcium phosphate (O), microcrystalline cellulose (Ф), 
lactose (A), corn starch (u), methylcellulose (A); mean curves, n = 6. 
The compression force used affected the dissolution from calcium phosphate 
based capsules most. The highest force (30 kg) retarded dissolution considerably 
(Fig. 3). Use of the various compression forces also retarded dissolution from corn 
starch based capsules (Fig. 4). When lactose was used as diluent, only the 
highest compression force had a retarding effect (Fig. 5). The capsules containing 
microcrystalline cellulose were most unaffected by the compression forces (Fig. 
6). 
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Flg. 3. Effect of compression on ibuprofen dissolution from capsules containing 200 mg of ibu­
profen and 300 mg of calcium phosphate. Compession forces: 0 kg (%), 10 kg (A), 20 kg (O) 
or 30 kg (a); mean curves, n = 6. 
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Flg. 4. Effect of compression on ibuprofen dissolution from capsules containing 200 mg of ibu­
profen and 200 mg of corn starch. Compression forces: 0 kg (Щ, 10 kg (A), 20 kg (O) or 
30 kg (O); mean curves, n= 6. 
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Flg. 5. Effect of compression on Ibuprofen dissolution from capsules containing 200 mg of Ibu­
profen and 195 mg of lactose. Compression forces: Окд(Щ, 10 kg (A), 20 kg (о) or 
30 kg (D); mean curves, n= 6. 
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Flg. 6. Effect of compression on ibuprofen dissolution from capsules containing 200 mg of Ibu­
profen and 10 mg of microcrystalline cellulose. Compression forces: 0 kg (Щ, 10 kg (A), 
20 kg (O) or 30 kg (U); mean curves, N = 6. 
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Flg. 7. Effect of compression on ibuprofen dissolution from capsules containing 200 mg of ibu­
profen and methylcellulose. Compression forces: 0 kg (Щ, 10 kg (A), 20 kg (O) or 
30 kg (a); mean curves, n = 6. 
When plugs were compressed from powder mixtures containing methylcellulose, 
the dissolution rate was slightly enhanced (Fig. 7). 
Changing the relative amounts of drug and diluent did not markedly alter the 
dissolution characteristics of the formulations studied, except in the case of 
methylcellulose (Fig. 8). 
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Flg. 8. Effect of relative amounts of ibuprofen and methylcellulose on dissolution of the drug from 
hard gelatin capsules (compression force 10 kg). Amounts of substances: 200 mg/155 mg 
(Щ, 100 mg /255 mg (A) or 50 mg / 305 mg (O); mean curves, n = 6. 
Discussion 
In a previous study, the dissolution characteristics of manually filled ibuprofen 
capsules were compared with those of capsules manufactured using a dosatortype 
filling machine mG2 (HANNULA et al. 1989). In that study, the manufacturing 
procedure (plug formation) had no significant effect on the dissolution of lactose 
or microcrystalline cellulose based ibuprofen capsules. Dissolution from calcium 
phosphate based capsules was slower from the automatically filled capsules than 
from the manually filled capsules. These findings are in good agreement with 
those reported here. 
The results of the study described in this paper and those reported by HANNULA 
etat. (1989) differ, however, when corn starch was used as diluent. In the study 
reported here, compression force led to decreases in dissolution rate. In the study 
of HANNULA etal., (1989) the dissolution rate from the automatically filled capsules 
was slightly higher than that from the manually filled capsules. 
The effect of compression on the dissolution of another drug sparingly water-
soluble, hydrochlorothiazide, from dicalcium phosphate and lactose based 
capsules has been studied by BOTZOLAKIS and AUGSBURGER (1983). The findings 
were in accordance with those reported here. Compression had no significant 
effect on dissolution from lactose based capsules but dissolution from calcium 
phosphate based capsules decreased with increase in compression force. The 
strength of the calcium phosphate plugs was higher than that of the lactose plugs. 
According to our experiences the equipment described is useful for preparing 
plugs from powder mixtures which simulate the plugs formed in dosator-type 
automatic capsule-filling machines. The parts necessary for construction of the 
assemby can be found in many laboratories in universities and pharmaceutical 
development departments. 
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Sodium alginates as diluents in hard gelatin capsules 
containing ibuprofen as a model drug 
P. VESKI and M. MARVOLA 
The object of the study reported here was to investigate 
the effects of 14 grades of sodium alginate (Manugels® 
and Manucols®) on the dissolution of ibuprofen from 
hard gelatin capsules. Three drug: additive ratios were 
investigated. Dissolution rates of each formulation 
followed zero-order kinetics. The rate constants varied 
in the Manugel series from 5.8 to 19.4% • h-1 and in 
the Manucol series from 8.0 to 58.8% • h"1. As a rule, 
the higher the viscosity grade of sodium alginate the 
lower the rate of release of ibuprofen. However, rank 
order correlation was not perfect. Particle size also 
seemed to have some effect: bigger particles gave less 
permeable gels. 
Natriumalginate als Verdünnungsmittel in Ibuprofen-
Hartgelatinekapsel 
Das Ziel der hier dargestellten Untersuchungen war die 
systematische Analyse der Wirkungen von 14 Natrium-
alginat-Qualitäten (Manugels® und Manucols®) auf 
die Lösung von Ibuprofen aus harten Gelatinkapseln. 
Drei Medikament/Hilfsstoff-Relationen wurden unter­
sucht. Für jede Zubereitungsform folgte die Lösungsge­
schwindigkeit einer Kinetik nullter Ordnung. Die Ge­
schwindigkeitskonstanten variierten in der Manugel-
Reihe von 5,8 bis 19,4% • h_1 und in der Manucol-
Reihe von 8,0 bis 58,8% • h~l. Als Regel gilt, daß sich 
mit höherem Viskositätsgrad des Natriumalginats die 
Freisetzungsrate des Ibuprofens verringert. Die Rang­
ordnungskorrelation war jedoch nicht vollkommen. Die 
Partikelgröße scheint ebenfalls einige Auswirkungen zu 
haben: größere Partikeln führten zu verringerten Gel­
durchlässigkeiten. 
1. Introduction 
Sodium alginates are hydrophilic polysaccharides produced 
from selected species of brown seaweeds. Structurally, they 
are linear copolymers containing two types of sugar residue: 
D-mannuronate (M) and L-guluronate (G) that occur in 
alginate molecules in three types of sequence: poly-M, poly-G 
and poly-MG [1]. Sodium alginates are widely used in the 
food industry. They have also been intensively studied as 
additives to solid and liquid drug products for peroral 
administration. 
It is common in scientific papers for the term sodium alginate 
to be used without qualification. However, there are many 
different types of sodium alginate on the market. These differ 
from each other in chemical and physical characteristics. Well 
known among the many manufacturers of sodium alginates 
is Kelco, which markets two series of alginates under the trade 
names Manugel® and Manucol®. The Manugel alginates are 
rich in guluronic acid, the Manucol alginates rich in mannur-
onic acid. The various grades in the two series differ from 
each other in particle sizes and viscosity [1]. 
Ibuprofen is a nonsteroidal anti-inflammatory drug used for 
relief of acute pain but also in chronic diseases such as 
rheumatoid arthritis. Its elimination half-life is very short 
(about 2 h) [2]. There is therefore a need for sustained-release 
formulation of ibuprofen. 
Sodium alginate, mostly no more precisely specified, has been 
studied as an additive in peroral sustained-release formula­
tions. For example, Timmins et al. [3] studied two grades of 
sodium alginate for use as a hydrophilic polymer in manu­
facturing verapamil matrix tablets. Alginate-based prolonged-
release theophylline tablets [4] and suspensions (5] have also 
been studied. In addition, sodium alginate has been used in 
microencapsulation, to achieve prolongation of drug release 
[6-9]. Stockwell et al. [10] prepared buoyant capsules contai­
ning sodium bicarbonate and sodium alginate as additives. 
The object of the study reported here was to investigate the 
effects of 14 grades of sodium alginate (Manugels or Manucols) 
on dissolution of an acidic model drug (ibuprofen) from hard 
gelatin capsules. If prolonged drug release were obtained, the 
formulations studied would be a simple way to produce 
sustained-release drug products. 
2. Investigations, results and discussion 
Tables 1 and 2 contain the properties of the alginates and the 
compositions of the capsules studied. 
Table 1 Properties of Manugels as stated by the manufacturer and 
compositions of tbe capsules studied 
Designa- Viscosity Particle Amount of Amount of Relative 
ibuprofen Manugel amount of 
Manugel [mPa s] lumI ImgJ (mg) Manugel 
DPB 500 355 100 345 0.78 
200 143 0.42 
250 103 0.29 
DMB 300 150 100 358 0.78 
200 171 0.46 
250 49 0.16 
DJX 200 75 100 257 0.72 
200 115 0.37 
250 64 0.20 
GMB 180 355 100 340 0.77 
200 151 0.43 
250 81 0.24 
DJB no 150 100 339 0.77 
200 165 0.45 
250 69 0.22 
GHB 75 355 100 363 0.78 
200 153 0.43 
250 78 0.24 
2.1. Weight uniformity 
Table 3 shows the results relating to formulations containing 
Manugels as diluent. Table 4 shows the results relating to 
Manucol-based capsules. All formulations met the weight-
uniformity specifications of the European Pharmacopoeia. 
The relative standard deviations varied from 1.4% to 4.2%, 
i.e. weight uniformity for most formulations was good. 
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Table 2 Properties of Manucols as stated by tbe manufacturer and 
compositions of the capsules studied 
Designa-
Manucol 
Viscosity Particle 
(1% sol.) size 
[mPa s) [>im] 
Amount of 
ibuprofen 
Amount of Relative 
Manucol amount of 
[mg] Manucol 
DMF 
DM 
SS/LL 
LKX 
LHF 
LF 
LD 
LB 
300 
250 
215 
150 
60 
25 
150 
35 
355 
63 
150 
355 
355 
355 
100 
200 
250 
100 
200 
250 
100 
200 
250 
100 
200 
250 
100 
200 
250 
100 
200 
250 
100 
200 
250 
100 
200 
250 
367 
125 
97 
398 
155 
67 
372 
118 
83 
343 
134 
74 
313 
209 
113 
486 
223 
130 
419 
186 
102 
391 
179 
150 
0.79 
0.38 
0.28 
0.80 
0.44 
0.21 
0.79 
0.37 
0.25 
0.77 
0.40 
0.23 
0.76 
0.51 
0.31 
0.83 
0.53 
0.34 
0.81 
0.48 
0.29 
0.80 
0.47 
0.38 
Dissolved [°/oJ 
Fig. 1. Dissolution of ibuprofen (200 mg) from hard gelatin capsules containing 
Manugel as diluent (means of 6 parallel tests). 1: GHB, 2: DJB, 3: GMB, 
4: DJX, 5: DMB, 6: DPB 
2.2. Dissolution rate and profile 
Figures 1 and 2 illustrate drug dissolution from capsules each 
containing 200 mg of ibuprofen. Dissolution kinetics are 
zero-order for each composition. Release also followed zero-
order kinetics for formulations containing 100 mg or 250 mg 
of ibuprofen. Rate constants, relative standard deviations and 
T80% values for Manugel-based capsules are shown in Table 
3. The corresponding values for Manucol-based capsules are 
shown in Table 4. Its is evident that release rates of ibuprofen 
can be varied markedly through appropriate choice of chemi­
cal and physical properties of sodium alginate. 
Dissolved Ы 
120-
Fig. 2. Dissolution of ibuprofen (200 mg) from hard gelatin capsules containing 
Manucol as diluent (means of 6 parallel tests). 1: LB, 2: LD, 3: LF, 4: LHF, 
5: LKX, 6: SS/LL, 7: DM, 8: DMF 
Table 3 Weight uniformity of 25 capsules and dissolution of ibuprofen from 6 to 12 capsules containing Manugels as diluent 
Designation 
of 
Manugel 
Amount of 
ibuprofen 
Capsule weight Rate constant, k0 Tsox 
mean [mg] s„, [%| mean [% • h"1] s„, 1%) (hi 
DPB 100 545 2.6 5.82 5.3 13.7 
200 443 2.5 8.27 3.5 9.7 
250 453 2.5 8.42 15.9 9.5 
DMB 100 558 2.5 6.24 14.9 12.8 
200 471 3.0 11.24 12.8 7.1 
250 399 2.2 16.89 8.8 4.7 
DJX 100 457 1.4 11.28 7.7 7.1 
200 415 1.5 13.94 17.8 - 5.7 
250 '414 2.7 19.42 14.8 4.1 
GMB 100 540 3.0 7.64 9.4 10.5 
200 451 2.3 9.71 25.6 8.2 
250 431 2.5 12.04 22.3 6.6 
DJB 100 539 2.7 10.17 5.4 7.9 
200 465 1.9 14.01 11.1 5.7 
250 419 1.8 18.71 10.6 4.3 
GHB 100 563 3.3 11.11 4.5 7.2 
200 453 13 16.48 23.3 4.8 
250 428 2.7 19.40 20.7 4.1 
k0 - zero-order rate constant for dissolution of ibuprofen, Tsox - time for 80% of ibuprofen to be dissolved 
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Table 4 Weight uniformity of 25 capsules and dissolution of ibuprofen from 6 to 12 capsules containing Manucols as diluent 
Designation Amount of Capsule weight Rate constant, k0 T 
of ibuprofen 
Manucol mean [mg] s„, [•/.] mean [•/• h™1) s„, ['/•] [hi 
DMF 100 567 3.0 10.04 8.7 8.0 
200 425 2.2 18.21 8.5 4.4 
250 447 3.4 18.95 10.0 4.2 
DM 100 598 3.1 8.44 11.9 9.5 
200 455 2.8 13.15 10.2 6.1 
250 417 15 17.67 11.2 4.5 
SS/LL 100 572 2.8 8.02 18.2 10.0 
200 418 2.2 14.74 17.9 5.4 
250 433 4.3 18.91 6.9 4.2 
LKX 100 543 1.6 12.90 14.0 6.2 
200 434 1.8 21.07 17.7 3.8 
250 424 2.4 23.83 6.4 3.4 
LHF 100 513 1.7 20.46 8.5 3.9 
200 509 2.8 20.26 14.1 4.0 
250 463 2.5 19.14 6.1 4.2 
LF 100 686 2.3 18.60 11.9 4.3 
200 523 3.3 21.17 17.0 3.8 
250 480 2.0 27.00 16.4 3.0 
LD 100 619 4.2 27.86 15.3 2.9 
200 486 3.2 33.77 15.9 2.4 
250 452 2.3 47.42 7.2 1.7 
LB 100 591 3.6 35.35 16.5 2.3 
200 479 3.7 58.79 16.1 1.4 
250 500 1.4 57.45 13.1 1.4 
k0 = zero-order rate constant for dissolution of ibuprofen, Te0% = time for 80% of ibuprofen to be dissolved 
Dissolution of ibuprofen from hard gelatine capsules contai­
ning hydrophilic polymers as diluents has previously been 
studied. Use of different grades of hydroxypropylmethyl-
cellulose (HPMC) resulted in square-root-of-time release 
kinetics. With many grades of sodium carboxymethylcellulose 
(NaCMC) fairly good fits to zero-order kinetics were obtained 
[11]. Release of chlorpheniramine hydrochloride from buoyant 
capsules containing different amounts of Manugel DMB 
obeyed square-root-of-time kinetics [10]. The present finding 
about zero-order release kinetics is desirable just for sustained-
release drug products. 
T8o% values for dissolution of ibuprofen from the sodium 
alginate based capsules showed here were similar to T80% 
values for analogous NaCMC-based capsules but markedly 
lower than those for HPMC-based capsules (for which T80o/o 
is more that 20 h) [11]. It is evident that release of ibuprofen, 
a weak acid, is faster from sodium alginate and NaCMC based 
capsules simply because of the anionic nature of the polymers. 
In contrast HPMCs are non-ionic polymers, and their use 
results in markedly slower release rates of acidic drugs. 
Zero-order release of ibuprofen seems to be related to use of 
anionic and sodium-containing polymers. Dissolution profiles 
from HPMC based capsules have followed best square-root-
of-time kinetics [11]. 
2.3. Differences between Manugels and Manucols 
As a rule, release of ibuprofen from Manugel based capsules 
was slower than that from capsules containing the equivalent 
viscosity grade of Manucol. This is in accordance with findings 
with Manugel DMB and Manucol DMF based tablets of 
verapamil hydrochloride [3]. Manugels are rich in guluronic 
acid. This has been said to form more rigid gels when hydrated 
than Manucols, which are rich in mannuronic acid [1]. Such 
more rigid gels may be less prone to erosion and constitute 
a more effective barrier to release of a drug by diffusion. 
Dissolution of verapamil hydrochloride from Manugel DMB 
based matrix tablets has been observed to be pH-dependent, 
the lower the pH the faster the dissolution rate [3]. In 
analogous studies with tablets containing Manucol DMF pH 
(1.2 or 7.4) of the solvent had no effect on rate of dissolution. 
In the study reported here, the pH was 7.2, much higher than 
gastric pH. The effect of pH on the dissolution rate of ibuprofen 
could not be investigated because of the solubility of the drug 
in acidic media is very low. Ultimate assessment of the value 
of Manugel-based capsules as a sustained-release dosage form 
for ibuprofen must therefore await availability of results of in 
vivo tests. 
2.4. Effect of drug: diluent ratio 
The correlation between the release rate constant (k0) and the 
relative amount of sodium alginate in the capsule was app­
roximately linear (see Table 3). Through appropriate choice 
of drug: diluent ratio the drug release-rate constant can be 
adjusted, e.g. with Manugel DMB from 6.2 to 16.9% • h_1. 
Viscosity [mPa-sJ 
Fig. 3. Correlation between release rate constants (k0) and viscosity grades of 
Manugel. 100 mg (1), 200 mg (2), 250 mg (3) of ibuprofen 
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This finding is in accordance with findings concerning 
drug release from buoyant capsules containing sodium 
bicarbonate and various amounts of Manugel DMB [10]. In 
that study, however, the correlation between the release rate 
constant and the reciprocal of the amount of alginate was 
most linear. 
2.5. Effect of viscosity grade 
In Figs. 3 and 4, the release rate constants are plotted against 
viscosity grades of Manugels and Manucols. Correlation was 
only slight. Both curves are biphasic. The greatest deviation 
from linearity was evident in the case of Manugel DJX. Release 
rate constants from capsules containing this were markedly 
lower than those expected on the basis of the viscosity grade. 
Viscosity grade alone is therefore an inappropriate parameter 
for use in selecting alternative sources of sodium alginate for 
inclusion in sustained-release hard gelatin capsule formula­
tions. This conclusion is in accordance with findings relating 
to matrix tablets of containing three grades of sodium alginate 
[3]. 
2.6. Effect of particle size 
Because the grades of Manugels and Manucols studied all 
differed from each other as regards viscosity grade, it is difficult 
to draw conclusions about the effect of particle size alone. An 
tendency to slower drug release with grades of bigger particle 
size was evident in the Manugel series (Fig. 5). The abnormal 
behaviour seen with Manugel DJX may be related to its very 
small mean particle size (75 цт). In the Manucol series, there 
was no correlation between drug release rate and particle size 
(Tables 2 and 4). 
2.7. Conclusions 
Dissolution of ibuprofen from all formulations studied, contai­
ning various grades of sodium alginate, closely followed 
zero-order kinetics. Such release is desirable in sustained-
release drug products. Release rates could be adjusted over a 
very wide range by choice of sodium alginates with different 
chemical and physical properties. In addition, altering of the 
drug: diluent ratio was an additional means of adjusting drug 
release rate. Manufacturing of the formulations studied, both 
small and large scale, is simple. 
50-
40-
30-
20-
10-
100 ) 200 
Viscosity [mPa-s] 
300 
Fig. 4. Correlation between release rate constants (k0) and viscosity grades of t  
Manucol. Symbols as in Fig. 3 
k0[°/=-h"1] 
20-
300 200 400 XX) 
Particle size [цт] 
Fig 5. Correlation betwen release rate constants (k0) and mean particle sizes 
of Manugels 
3. Experimental 
Size 0 hard gelatin capsules (Posilock®, Elanco, USA) were used for all 
formulations. Amounts of Ibuprofen (Medipolar. Finland) required were weighed 
in a graduated cylinder and the diluent was added to produce sufficient 
material for batches of 25 capsules (17 ml). The powder was mixed and dispensed 
into Capsula shells manually. Sodium alginates sold under the trade names of 
Manugel and Manucol (Kelco Ltd, U.K.) were used. The compositions of the 
formulations studied and the viscosity grades and particle sizes of the sodium 
alginates used are shown in Tables 1 and 2. Weight uniformity of filled capsules 
was determined using 25 capsules, according to the European Pharmacopoeia. 
Dissolution of ibuprofen from the capsules was determined using the USP 
rotating basket method as described for ibuprofen tablets in USP XXII 
(Prolabo, France). The solvent was phosphate buffer pH 7.2 (900 ml at 37 °C). 
The speed of rotation was 150 min"'. The dissolution apparatus was connected 
via a peristaltic pump (Watson-Marlow 503S, Smith & Nephew, U.K) to a 
flow-through spectrophotometer (Ultrospect 11, LKB Biochrom Ltd., U.K.). 
The pump was operated at a delivery rate of 7 ml • min-1. The absorbances 
of drug solutions in 2 mm flow-through cells at 221 nm were recorded 
automatically at regular intervals. The reference cell contained solvent saturated 
with the grade of sodium alginate used as diluent in the formulation concerned. 
Measurements were monitored using a computer running tablet dissolution 
software (TDS®, LKB Biochrom Ltd., U.K.). Release data were fitted to 
zero-order kinetics curves using MINSQ software (Micromath, USA). 
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SUMMARY 
The paper deals with bioavailability studies of hard gelatin capsules containing 
ibuprofen as drug and different viscosity grades of sodium alginate as diluent. 
Tests were carried out on healthy volunteers. It was concluded that with different 
viscosity grades of sodium alginate it is possible to prepare ibuprofen capsules 
from which the absorption rate of the drug can be controlled over a fairly wide 
range without any fall in the amount of drug absorbed. The correlation between the 
in vitro release rate constant ко and the in vivo absorption rate parameter 
C^/AUC was excellent The procedure is a simple and inexpensive way to 
produce a prolonged-release drug product. In addition, it is possible that sodium 
alginate may protect the gastric mucosa from the irritating action of anti­
inflammatory analgesics. This would be an extra advantage for the formulations 
described here. 
INTRODUCTION 
2 
Ibuprofen [d,l-2-(4-isobutylphenyl)propionic acid] is a nonsteroidal anti­
inflammatory drug used for relief of acute pain but also for pain relief in chronic 
diseases such as rheumatoid arthritis and osteoarthritis. Ibuprofen is rapidly and 
completely absorbed after peroral administration. In studies with peroral solutions, 
peak plasma concentrations have been achieved at 0.5-0.7 h (1-3). For 
conventional tablets t^ values of 1.3 to 2.7 h have been reported (1, 4-9). 
For relief of acute pain, rapid drug absorption is usually desirable. When anti­
inflammatory analgesics are used in chronic disease rapid drug absorption is 
frequently avoided because it may result in systemic side effects due to high peak 
levels of the drug. Most important in this situation is a high degree of absorption, 
not a high absorption rate. Prolonged-release ibuprofen formulations have been 
prepared dispensing coated pellets into hard gelatin capsules (7, 10). In our 
previous studies we have developed ways of preparing prolonged-release ibuprofen 
capsules using different hydrophilic polymers or other gel-forming agents as a 
diluent (3, 11, 12). 
Nonsteroidal analgesics like ibuprofen may also irritate the gastric mucosa. In 
theory, this kind of side effect can be avoided by protecting the mucosa with a gel-
forming drug like sodium alginate (13). Sodium alginate has also been widely used 
as an additive in solid or liquid peroral drug products. Prolonged-release matrix 
tablets containing sodium alginate have been prepared from verapamil 
hydrochloride (14) and theophylline (15). 
Although there are many different types of sodium alginate on the market, many 
scientific papers use the term sodium alginate without being more specific. In our 
previous paper we studied the effect of 14 specified grades of sodium alginate on 
the dissolution of ibuprofen from hard gelatin capsules (16). It was noted that the 
release of ibuprofen obeyed zero-order kinetics and was, as a rule, dependent on 
the viscosity grade of the sodium alginate. The rate constant k<, varied from 5.8 to 
57.5 %-h'1. 
The aim of the study reported here was to investigate whether it is possible to 
prepare, using four different grades of sodium alginate as diluent, ibuprofen 
capsules which provide prolonged release of the drug in vivo. A further aim was 
to determine whether the previous in vitro results correlate with the present results 
from bioavailability tests in man. 
MATERIAL AND METHODS 
3 
Capsule formulations 
Size 0 hand gelatin capsules (Posilock™, Elanco, USA) were used for all 
formulations. The amount of ibuprofen (Medipolar, Finland) per capsule was 200 
mg. Four different viscosity grades of sodium alginate (Kelco Ltd, U.K.) were 
used a diluent. The trade names and the viscosities of 1% aqueous solutions of 
these sodium alginates were: Manugel DPB (500 mPa-s), Manugel GHB (75 
mPa-s), Manucol DM (250 mPa-s), and Manucol LD (9 mPa-s). The particle size 
of all sodium alginates were the same (mean 355 jam). 
The necessary amount of drug was weighed in a graduated cylinder and the 
diluent was added to produce sufficient material for a batch of 25 capsules (17 
ml). The amounts of sodium alginate per capsule were: Manugel DPB 143 mg, 
Manugel GHB 153 mg, Manucol DM 155 mg and Manucol LD 186 mg. The 
powder was mixed manually and the capsules were filled using a Feton apparatus. 
Bioavailability study 
Two groups of eight volunteers (five women and three men in group I, four 
women and four men in group П) participated in two randomized cross-over single 
dose studies, which were carried out in accordance with the recommendations of 
the Declaration of Helsinki (World Medical Assembly 1975) as revised in Tokyo. 
The ages of the volunteers varied from 19 to 25 years and the weights from 45 to 
84 kg. All were non-smokers and did not take any drug during the study or one 
week before it. One week prior to the study the participants underwent a physical 
examination, routine laboratory tests and an ECG. The study protocol was 
approved by the ethical committee of the University of Tartu. 
Each formulation (two 200 mg capsules) was administered with 200 ml of water 
following an overnight fast A standard lunch was provided 3 h after drug 
administration. Group I was administered capsules containing Manugels and group 
II capsules containing Manucols. The wash-out period between the formulations 
was one week. 
Blood samples of 10 ml were collected via a forearm vein into heparinized tubes 
just prior to drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 h after drug 
ingestion. Plasma was separated approximately 30 min after .collection by 
centrifugation (3000 g for 10 min), and frozen at -20°C until analyzed. 
Plasma assay 
Ibuprofen plasma concentrations were determined by means of high performance 
liquid chromatography (HPLC), using a slightly modified version of the method of 
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Avgerinos and Hütt (17). Each plasma sample was analyzed in duplicate and the 
mean value was used. The system was equipped with a Waters Model 510 piston 
pump, a Waters Intelligent Sample Processor Model 700, a Waters Model 484 
Tunable Absorbance Detector operating at 222 nm, a Waters Model 820 Maxima 
Workstation (Waters Ltd, USA) and a Hibar column packed with Lichrosorb (10 
pm, C18 reversed phase 240-4, E.Merck, Germany). The mobile phase was 
acetonitrile and 0.1 M sodium acetate (35:65), adjusted to pH 6.2 with glacial 
acetic acid. All chemicals were analytical or HPLC grade. The flow rate was 2 
ml min '1. 
A series of standard plasma ibuprofen curves was prepared over the 
concentration range 2.0-80.0 mgi"1. All standard curves were linear over the range 
examined (r > 0.99) and passed close to the origin. The accuracy and precision 
were tested by analyzing seven samples of blank plasma spiked with 32.0 mgi"1 
of ibuprofen. The inaccuracy was 1.4% and the imprecision 3.0%. The quantitation 
limit was 2.0 mg-Г1 (C.V. for precision less than 20%, n = 5). No interfering 
peaks were observed in the plasma blanks. 
Pharmacokinetic parameters 
The following pharmacokinetic parameters were assessed using the Siphar™ 
program (Simed, France): maximum plasma concentration (Cmax), time to peak 
concentration (!„,„), area under the concentration-time curve from time 0 to infinity 
(AUG), elimination half-life (t^) and mean residence time (MRT). The ratio 
Qnax/AUC was also calculated. Statistical analyses were carried out using Student's 
t-test or Student's paired t-test. t^ values were analyzed using Wilcoxon's test 
RESULTS 
Individual plasma levels of ibuprofen after ingestion of the four different 
formulations studied are shown in Fig. 1. The corresponding mean curves are 
presented in Figs. 2 and 3. The results of the pharmacokinetic calculations are 
given in Table I. Table II contains the results of the statistical evaluations. The 
extent of bioavailability of ibuprofen evaluated on the basis of the AUG values 
was the same from each formulation. In contrast, statistically significant 
differences were observed many times in the parameters reflecting the rate of 
bioavailability (V, Cmax, MRT and Cmax/AUC). 
In our previous study (16) the dissolution rate of ibuprofen from the 
formulations, which were the same as those studied here, was shown to obey zero-
order kinetics. The rate constants (ко) were: 8.27 %-h'1 (Manugel DPB), 13.15 
%-h"1 (Manucol DM), 16.48 %-hl"1 (Manugel GHB) and 33.77 %-h"1 (Manucol 
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Fig. 1: Individual plasma concentrations of ibuprofen after administration of 400 
mg in different capsule formulations. 
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Fig. 2: Mean plasma concentrations of ibuprofen after administration of 2 x 200 
mg capsules containing two different grades of sodium alginate: * Manucol LD, 
• Manucol DM. Means ± S.E.M., n = 8. 
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Fig. 3: Mean plasma concentrations of ibuprofen after administration of 2 x 200 
mg capsules containing two different grades of sodium alginate. * Manugel GHB, 
• Manugel DPB. Means ± S.E.M., n — 8. 
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Table I. Pharmacokinetic parameters of ibuprofen from hard gelatin capsules containing 
different sodium alginates as diluent. Single dose of two capsules (total 400 mg), mean ± S.D., 
n = 8. 
Parameter 
Diluent 
Manugel DPB Manugel GHB Manucol DM Manucol LD 
Cm„ (mgi1) 
Ux GO 
AUG (mgi1*) 
t* (h) 
MRT (h) 
Cmax/AUC (h1) 
19.0 ± 5.48 
4.88 ± 2.83 
194 ± 105 
5.75 ± 4.23 
10.8 ± 6.83 
0.17 ± 0.02 
23.6 ± 6.27 
3.75 ± 1.90 
158 ± 42 
3.81 ± 2.46 
7.50 ± 4.41 
0.19 ±0.03 
21.0 ± 8.76 
3.25 ± 0.70 
145 ± 59 
3.66 ± 1.37 
7.13 ± 2.18 
0.18 ± 0.03 
31.4 ± 11.1 
1.94 ± 0.93 
146 ± 67 
2.45 ± 0.56 
4.68 ± 1.09 
0.24 ± 0.05 
Table П: Statistical evaluation of the calculated pharmacokinetic parameters for ibuprofen 
capsules containing different sodium alginates as diluent. The formulation with the highest 
release rate (containing Manucol LD) was used as reference. 
Parameter 
Diluent 
Manucol DM Manugel GHB Manugel DPB 
с '-max 
* * ** 
tmtx ** ** ** 
AUG NS NS NS 
t* NS NS * 
MRT NS * ** 
Cnux/AUC * * * 
* = p<0.05, ** = p<0.01, NS = not significant 
18 
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LD). The correlation of this in vitro parameter to the pharmacokinetic parameters 
calculated here was tested by means of the linear correlation test. The best linear 
correlation was found between the ratio CmM/AUC and ко (Fig. 4). The equation 
was у = 0.15 + 0.0028x and the correlation coefficient 0.999. Almost the same 
correlation was found between Cmix and ky (r = 0.997). With the other rate 
parameters (TniU and MRT) the correlation was poorer. Not even a rank-order 
correlation was found, as can be seen from the values in Table I. 
0.30 
-C 
0.20 
0.10 
0.00 1 1 1 1 1 1 1 
О 10 20 30 40 
DISSOLUTION RATE CONST ANT % / h 
Fig. 4: In vitro/in vivo correlation between dissolution rate constant ко and 
absorption rate parameter CmJA\JC of the four ibuprofen capsule formulations 
studied 
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DISCUSSION 
When the lowest viscosity grade of sodium alginate (Manucol LD) were used as 
diluent, the absorption profile of ibuprofen did not differ markedly from that 
achieved for conventional ibuprofen tablets or capsules (1, 4-9). The mean t^ 
values have been 1.3 to 2.7 h and the Cmax values 23.3 to 31.4 mgi"1 as compared 
with 1.94 h and 31.4 mgi"1 for Manucol LD capsules in the present study. The 
elimination half-life of ibuprofen from immediate release formulations has been 
reported to be 1.5 to 2 h (2, 9, 12). For Manucol LD capsules t* was 2.45 h. The 
conclusion is that Manucol LD, although slightly lowing the in vitro release rate 
of ibuprofen, does not markedly prolong the absorption of the drug. 
The higher viscosity grades of sodium alginate (Manucol DM, Manugel GHB 
and especially Manugel DPB) led to a noticeable prolongation of drug absorption. 
Statistically significant differences were seen in t^, Cmax, Cmax/AUC and MRT 
values of capsules containing Manugels (Table II). The t^ of Manugel DPB 
capsules also differed significantly (P<0.05) from that of Manucol LD capsules. 
Thus, ibuprofen capsules containing Manucol DM or Manugel GHB can be 
classified as slow-release products, but capsules containing Manugel DPB as an 
extended-release product. 
The difference between the four formulations can also be seen from the mean 
curves in Figs. 2 and 3. The individual plasma curves in Fig. 1 show a substantial 
interindividual variation. It is typical that one or two individuals differ from the 
rest This is not a desirable characteristic for a prolonged-release product. The 
variations in pharmacokinetic parameters given as standard deviations in Table I 
are greater than those for ibuprofen capsules containing different viscosity grades 
of hydroxypropylmethylcellulose as diluent (12). However, the present distribution 
of individual plasma curves is not extraordinary in comparison with many other 
prolonged-release formulations. 
Of the many pharmacokinetic parameters reflecting the absorption rate, one of 
the newest is the ratio C^/AUC. It is said to be especially applicable when 
modified-release products are examined (18). As seen in Fig. 4, the correlation of 
this parameter to the in vitro parameter ко is excellent. 
It can be concluded that with different viscosity grades of sodium alginate it is 
possible to prepare ibuprofen capsules from which the absorption rate can be 
controlled over a fairly wide range without any fall in the amount of drug 
absorbed. This is a simple and inexpensive way to produce prolonged-release drug 
products. In addition, sodium alginate may protect the gastric mucosa from the 
irritating action of anti-inflammatory analgesics, which would be an extra 
advantage for the formulations described here. 
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Abstract 
The aim of the study described here was to develop prolonged-reiease press-coated tablets containing ibuprofen. 
The drug dose was divided between the core and the coat in the ratio 2:1. Different chemical types, viscosity grades 
and amounts of sodium alginate were used in the coat to control drug release. Each of the variables studied affected 
the drug release rate. The in vitro release profiles were biphasic. The initial release rate was slow and in most cases 
increased with time. The terminal phase obeyed zero-order kinetics. The in vivo absorption profiles were also 
biphasic but both the initial and the terminal phases were markedly more rapid than in the in vitro dissolution 
studies. It was concluded that with different sodium alginates it is possible to prepare press-coated tablets from 
which the absorption rate can be controlled over a fairly wide range from an immediate release formulation via slow 
release formulations even to an extended-release formulation. 
Key words: Bioavailability, Compression coating; Ibuprofen; Prolonged release; Sodium alginate 
1. Introduction 
In the development of prolonged-release drug 
products, it is common to attempt to achieve 
constant drug levels in the blood for as long as 
possible, on the assumption that the therapeutic 
effects will consequently be optimal. However, 
many diseases have marked diurnal rhythms. In 
such diseases, therapeutic drug concentrations 
should vary during the day. Drug levels should be 
highest when the symptoms are most severe. For 
example, in rheumatism, early morning stiffness 
is common. In theory, maximum drug levels can 
be achieved early in the morning if a formulation 
from which drug release increases with time is 
administered the previous evening. 
Our previous studies (Sirkiä et al., 1992, 1993a) 
shown that it is possible to prepare pro-* Corresponding author. Fax 358-0-191 2786. ha 
0378-5173/94/S07.00 О 1994 Elsevier Science B.V. All rights reserved 
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longcd-release furoscmide and saibutamol tablets 
using a compression-coating technique from 
which the in vitro drug release rate increases with 
time. The total amount of drug in each tablet was 
'divided between (he core and the coat in the 
ratio 2:1. Drug release rate could be controlled 
principally by variation of the amount of polymer 
in the coat. In the "fiKt two studies the polymer 
used was hydrophilic hydroxypropylmethylcellu-
lose (HPMC). The next study (Sirkiä et al., 1993b) 
used other hydrophilic polymers (sodium car-
boxymethylcellulose (NaCMC) and Carpobol 
934P) but they did not control drug release as 
expected. 
In the study described here, the polymer used 
to control drug release was sodium alginate. In 
previous investigations different viscosity grades 
of sodium alginate were successfully used as addi­
tives in the preparation of prolonged-release hard 
gelatin capsules of ibuprofen (Veski and Marvola, 
1993; Veski et al., 1993). Alginates are anionic 
polysaccharides produced from selected species 
of brown seaweed. They are linear block copoly­
mers containing two types of sugar residue, 
namely o-mannuronate (M) and L-guluronate (G). 
Three types of sugar residue sequence occur in 
the alginate molecules poly-M, poly-G and poly-
MG. In this study we used two different types of 
sodium alginate sold under the trade names 
Manugel™ or Manucol™. Manugels contain a 
relatively high proportion of poly-G sequences 
and Manucols a low proportion of poly-G se­
quences (McDowell, 1986). 
In the present study ibuprofen was used as a 
model drug. It is a nonsteroidal anti-inflamma­
tory drug (NSAID) used for relief of acute pain 
and also in chronic diseases such as rheumatoid 
arthritis. Ibuprofen is readily absorbed through­
out the gastrointestinal tract (Wilson et al., 1989) 
and its elimination half-life is only about 2 h 
(Ritschel, 1986). 
The aim of this study was to investigate the 
suitability of sodium alginate for the press-coated 
tablet system developed, and to study by means 
of in vitro dissolution tests how the amount and 
the viscosity grade of sodium alginate affect drug 
release. The release rate of the drug from the 
tablet system prepared should ideally increase to 
a maximum at about 6 h. Finally, the bioavailabil­
ities of the formulations judged to be the best 
were studied in man. 
2. Materials and methods 
2.1. Materials 
Four different viscosity grades of sodium algi­
nate - Manugel GHB (75 mPa s), Manugel DPB 
(500 mPa s), Manucol LF (25 mPa s) and Manu­
col DM (250 mPa s) - manufactured by Kelco 
Ltd, U.K. were used to control drug release. The 
values in parentheses are the viscosities of 1% 
aqueous solutions of each alginate at 20°C. The 
mean particle size of each grade of alginate was 
355 /im. The model drug was ibuprofen (Orion-
Farmos Pharmaceutical, Finland). To ensure rea­
sonable dissolution of ibuprofen, which is spar­
ingly water-soluble, the core contained potassium 
carbonate (Carlo Erba, Italy). Other excipients 
were polyvinylpyrrolidone (PVP, K25 Fluka, 
Switzerland), directly compressible lactose 
(Pharmatose DCL 21, The Netherlands), magne­
sium stearate (EP) and talc (EP). 
22. Compositions 
The tablets, each consisting of a core and a 
coat, were prepared using the compression coat­
ing technique. The drug was divided between the 
core and the coat in the ratio 2:1. The total 
amount of ibuprofen was always 100 mg. Only the 
coat contained polymer (Manugel™ or Manu­
col™) to control drug release. The compositions 
were: 
Core Coat 
Ibuprofen 67 mg Ibuprofen 33 mg 
Potassium 20 mg Sodium alginate 300/340/360 mg 
carbonate 
Lactose 40 mg PVP-water-ethanol 10% ял. 
Magnesium 1% Magnesium stearate !% 
stearate 
Talc 2% Talc 2% 
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13. Preparation of tablets 
To prepare the core ibuprofen, potassium car­
bonate and lactose were mixed in a mixer 
frurbula AG, Swrkerland) for 10 min. Magne­
sium stearate and talc were then added and mix­
ing was continued for another 2 min. The cores 
were compressed in a korsch EK-0 (Erweka Ap­
paratebau, Germany) single-punch machine, us­
ing concave 7-mm punches. The compression 
force used was 10-12 kN. 
Compression coating was performed manually 
using a Korsch EK-0 (Erweka Apparatebau, Ger­
many) single-punch machine equipped with 11-
mm punches. Ibuprofen and polymer were mixed 
in a mixer (Turbula AG, Switzerland) for 10 min. 
The powder mass was moistened with 10% PVP-
water-ethanol solution and then sieved through a 
0.7 mm sieve. The granules were dried overnight 
at 35eC. For tabletting, the fraction 0.3-0.7 mm 
was used. Magnesium stearate and talc were 
mixed with the granules in the same mixer for 2 
min. Half of the granules for one tablet were 
weighed into the die and the core was placed on 
the granule bed. The rest (50%) of the granules 
were added to the die and tbe tablet was com­
pressed manually using a force of about 20 kN. 
14. Dissolution studies 
The dissolution of ibuprofen was studied using 
the USP paddle method, as described for ibupro­
fen tablets in USP XXII (Dissolutest 07, Prolab, 
France). The dissolution medium was phosphate 
buffer, pH 7.2 (900 ml at 37 ± 0J°C) and the 
speed of rotation was 50 min-1. The dissolution 
apparatus was connected to a flow-through spec­
trophotometer (Ultraspect II, LKB Biochrom Ltd, 
U.K.) via a peristaltic pump (Watson-Marlow 
503S, Smith and Nephew, U.K.). The absorbance 
of the dissolution medium in 2-mm flow-through 
cells at 221 nm was recorded automatically at 
regular intervals. Both absorbance measurements 
and pump were controlled by a computer running 
tablet dissolution software (TDS™, LKB Bio­
chrom Ltd, U.K.). The release rates in 1-h peri­
ods were shown graphically. The amount of 
ibuprofen released was measured from six paral­
lel samples. 
15. Bioavailability study 
Two groups of seven healthy volunteers partic­
ipated in randonlized cross-over single-dose stud­
ies, which were carried out in accordance with 
the recommendations of the Declaration of 
Helsinki (World Medical Assembly, 1975) as re­
vised in Tokyo. The ages of the volunteers varied 
from 19 to 25 years and the weights from 45 to 84 
kg. All were non-smokers and none took any drug 
during the study or 1 week before it. 1 week prior 
to the study the participiants underwent a physi­
cal examination, routine laboratory tests and an 
ECG. The volunteers were informed of the possi­
ble risks and side effects of the drug, and their 
written consent was obtained. The study protocol 
was approved by the ethical committee of the 
University of Tartu. 
Each formulation (4 x 100 mg tablets) was ad­
ministered with 200 mi of water following an 
overnight fast for at least 10 h. The washout 
period was at least 1 week. A standard lunch was 
provided 3 h after drug administration. Blood 
samples of 10 ml were collected from a forearm 
vein into heparinized tubes just prior to drug 
administration and 0.5, 1, 2, 3, 4, 6. 8,10 and 12 h 
thereafter. Plasma was separated approx. 0.5 h 
after collection and stored at - 20°C until analy­
sis. 
2.6. Plasma assay 
Ibuprofen plasma concentrations were deter­
mined by means of HPLC using the method 
described by Avgerinos and Hütt (1986), with 
slight modifications. The system was equipped 
with a Waters Model 501 piston pump, a Waters 
Model 717 Intelligent Sample Processor, a Wa­
ters Model 486 Tunable Absorbance Detector 
operated at 222 nm, and a Waters Model 820 
Maxima Workstation. Sample separation was car­
ried out on a /iBondapak C18 reverse-phase 125 
A column (3.9 X 300 mm). The guard column 
used was an RCSS /xBondapak C,K. The isocratic 
mobile phase was acetonitrile and 0.1 M sodium 
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acetate (35:65), tbe pH of which was adjusted to 
6.2 with glacial acetic acid. The flow rate was 2 
ml min"1. 
The standard curve was found to be linear 
NWer the concentration range 2-40 mg П1. The 
linear coefficient of determination was 0.998. The 
accuracy and precision of the method were inves­
tigated as recommended" (Shah et al., 1992) by 
analysing six plasma samples spiked with ibupro­
fen concentrations of 2 and 40 mg 1"The mean 
values were 2J33 mg l"1 (CV% 3.8) and 40.2 mg 
1-1 (CV% 5.8), respectively. The limit of quanti­
tation was estimated to be 2 mg l-1. No interfer­
ing peaks were observed in the plasma blanks. 
2.7. Pharmacokinetic parameters 
The pharmacokinetic parameters, assessed us­
ing a Siphar™ program (Simed, France), were 
maximum concentration (C^), time to peak 
concentration (*„„,), area under concentration 
time curve from 0 to infinity (AUC0-e), apparent 
elimination half-life (f1/2) and mean residence 
time (MRT). Cmix and rmM values were used as 
measured. AUC and MRT values were calculated 
according to the trapezoidal method without log­
arithmic transformation. The rate of the absorp­
tion phase was also evaluated by means of the 
ratio Cm../AUCn^.. Stastistical analyses were 
carried out using the Wilcoxon matched-pairs 
rank test and the Mann-Whitney U-test. 
3. Results and discussion 
The present formulation consists of two parts. 
The inner part, the core, is a conventional tablet 
containing most of the drug dose and thus acts as 
a drug reservoir. The outer part, the coat, con­
tains a small amount of the dose and a hy­
drophilic polymer which forms a gel layer around 
the tablet both in vitro and in vivo. In theory, 
drug release from the system can occur via two 
mechanisms: as a consequence of erosion of the 
gel layer or by means of diffusion through the gel 
layer (Alderman, 1984). Ibuprofen is a sparingly 
water-soluble drug and, according to Alderman, 
should be liberated mainly from the gel formed 
via erosion. On the other hand, the core also 
contains potassium carbonate an alkaline com­
pound that enhances the aqueous solubility of 
ibuprofen. Thus, diffusion of the dissolved drug 
through the gel layer is also a potential mecha­
nism for drug release. 
3.1. Effect of the chemical type and viscosity grade 
of sodium alginate on drug release 
The first variables studied were the effects of 
the chemical type and viscosity grade of sodium 
alginate. As seen in Fig. 1 a rank order correla­
tion existed between the viscosity grade of sodium 
alginate and the mean curves of the cumulative 
amounts of ibuprofen released; the higher the 
viscosity grade the lower the release rate. How­
ever, there was no marked difference between 
curves of tablets containing Manucol DM (viscos­
ity 250 mPa s) and tablets containing Manugel 
GHB (viscosity 75 mPa s). 
The conclusion is that the viscosity grade of 
sodium alginate is not the only parameter which 
predicts the release rate of ibuprofen from the 
present kind of formulation: the chemical struc­
ture of sodium alginate also has an effect. 
Manugels, which are composed of a relatively 
high proportion of polyguiuronate sequences, 
slowed down drug release more than Manucols, 
too 
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Fig. 1. Release of ibuprofen from press-coated tablets con­
taining different viscosity grades of sodium alginate: (д) 
Manucol LF, (O) Manucol DM. ( a ) Manugel GHB and (•) 
Manugel DPB. The amount of sodium alginate in the coat 
was always 360 mg. Each point is the mean±SD. л -6. 
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which are rich in poiymannuronate sequences. 
The same phenomenon has been noted in hard 
gelatin capsules containing different viscosity 
grades of Manucols and Manugels as diluents 
'•^Veski and Marvdåa, 1993). In addition, Murata 
et al. (1993) in their studies concerning the re­
lease of brilliant blue (BB) from alginate beads 
concluded that the "release of BB was slightly 
faster from the M-rich gel than from the G-rich 
gel, despite the similarity in the molecular weights 
of the polymers used. 
The changes in drug release profiles are best 
seen in Fig. 2, where release rate is plotted as a 
function of time. As far as Manucol LF tablets 
are concerned (Fig. 2, upper panel) it is evident 
that during the first 2 h the release rate was slow 
and constant, indicating drug release via erosion 
of the gel layer. Thereafter, at 3-4 h the release 
rate was very fast, indicating disintegration of the 
whole tablet. Although this is the kind of release 
profile sought in this study, the burst in drug 
release happened too early. 
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Fig. 1 Rate of drug release (per cent dissolved/h) vs time. (Upper panel) Manucols (cross-hatched bars) LF and (diagonally 
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With Manucol DM and Manugel GHB tablets, 
the changes in the release profile of Ibuprofen 
were identical. In both cases the release rate 
increased as a function of time up to 7 or 8 h 
'<!Fig. 2, upper ancNower panels). The same phe­
nomenon was observed in the cumulative amounts 
released in Fig. 1, where the drug release rates 
increase exponential!/ up to 7-8- h. The drug 
release rates from 8 to 12 h were constant or 
showed only a slight decrease (Manucol DM) 
from 7 to 11 h (Manugel GHB). It is obvious that 
the gel layer remained intact throughout and that 
the majority of the ibuprofen dose was released 
via diffusion through the gel layer. These two 
release profiles are in accordance with the aims 
of the present study. 
The tablets containing Manugel DPB in the 
coat behaved quite differently (Fig. 2, lower 
panel). This time the release rate of ibuprofen 
increased with time up to 9 h. Thereafter, the 
release rate obeyed zero-order kinetics up to 20 
h. This kind of release profile is understandable 
if after 9 h the drug release consists mainly of the 
diffusion of a saturated drug solution through the 
gel layer. This kind of release profile might be 
suitable for extended-release formulations. 
3.2 Effect of amount of sodium alginate on drug 
release 
Fig. 3 illustrates the effect of the amount of 
polymer on the release of ibuprofen. As can be 
seen, the amount affected the overall release rate 
but not the profile of the release curve. Stockwell 
et al. (1986), Takamura et al. (1992) and Mürata 
et al. (1993) have also studied the effect of the 
amount of sodium alginate on drug release. They 
concluded that an increase in the amount of 
sodium alginate in the matrix slows down the 
drug release rate. In our study, however, the 
amount of sodium alginate had only a minimal 
effect, much smaller than that of the viscosity 
grade of sodium alginate. 
3.3. Bioavailability of ibuprofen 
Individual concentration/time curves for all 
four formulations are depicted in Fig. 4. The 
corresponding mean curves are given in Fig. 5 
and the calculated pharmacokinetic parameters 
in Table 1. The interindividual variation in con­
centration/time curves was reasonable for each 
formulation, which is a desirable property for a 
modified-release preparation. Variation was low­
est in the Manucol DM tablet. 
As far as the extent of bioavailability of 
ibuprofen is concerned, no differences were found 
between the formulations. This is consistent with 
many other studies in which formulation factors 
have had no marked effect on the amount of 
ibuprofen absorbed (Regazzi et al., 1986; Mar-
vo!a et al., 1991; Ojantakanen et al., 1993). The 
present AUG values (mean 117-151 mg Г1) are 
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Fig. 3. Release of ibuprofen from press-coated tablets con­
taining different amounts of sodium alginate: ( + ) 300 mg, 
( a ) 340 mg and (•) 360 mg in the coats. Each point is the 
mean ± SD. я - 6. The polymers used were Manucol DM 
(upper panel) and Manugel DPB (lower panel). 
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Fig. 4. Individual blood concentration curves of ibuprofen after administration of dose via test preparations: (A) Manucol LF, (B) 
Manucol DM, (C) Manugel GHB and (D) Manugel DPB. 
of the same magnitude as reported in the papers 
mentioned above. 
The absorption rate of ibuprofen from differ­
ent preparations can be evaluated using the 
Cmtx and MRT values or the ratio C„„/AUC. 
As seen in Table 1, the highest statistically signifi­
cant differences were noted in the С /AUC 
values. This ratio is said to be a good parameter 
ТаЫе 1 
Pharmacokinetic parameters for the test preparations (means ± SD, л - 7) 
Parameter Manucol LF Manucol DM Manugel GHB Manugel DPB 
AUCUngl"1 h) 117 ±323 128 ±26.6 130 ±54.1 151 ± 449 
Cm (mgl-1) 27.6 ± 6J8 213 ± 3.82 * 213 ± 6.00 18.28 ± 520 * 
'пид (h) 171 ± 0.76 2-86 ± 0.69 339 ± 0.76 439 ± 135 * 
MRT (h) 4.72 ± 0.83 5.88 ± 1.03 634 ± 1.19 8.97 ± 332* 
Cbm/AUCq^OI" ') 0.24 ± 0.04 0.17 ± 0.01 h 0.17 ± 0.04 0.12 ± 0.04 u 
' 1/2 (h) 231 ± 0.31 2.87 ± 0.61 • 197 ± 0.73 4.71 ± 1.78" 
Wilcoxon matched-pairs rank test: * p < 0.05, p < 0.01 and ' p <0.001, Manucol LF vs DM or Manugel GHB vs DPB. 
Mann-Whitney non-parametric U-test: J p <0.05, 1 p < 0.001 and ' p < 0.001, Manucol LF vs Manugel DPB. 
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Fig. 5. Mean blood concentrations of ibuprofen after adminis­
tration of 400 mg via test preparations: (д) Manucol LF, (o) 
Manucol DM, (•) Manugel GHB and (•) Manugel DPB 
(means ± SE, n - 7). 
for evaluation of prolonged-release formulations 
(Schall and Luus, 1992). MRT is also a useful 
parameter, especially in cases where the drug 
(such as ibuprofen) eliminates rapidly. 
The pharmacokinetic characteristics of the for­
mulation containing Manucol LF were similar to 
those of conventional or immediate release for­
mulations. Its tmta value was 2.7 h and r1/2 value 
2.3 h. These differ only slightly from those re­
ported for commercial or experimental immedi­
ate release formulations of ibuprofen: 1.6-2.3 
h or r1/2 1.5-2 h (Gillespie et al., 1982; Lock­
wood et al., 1983; Karttunen et al., 1990; Saano et 
al., 1991; Ojantakanen et al., 1993). The clear 
peak concentrations seen in every volunteer in 
Fig. 4A are typical of immediate release prepara­
tions. 
The tablet containing Manucol DM can be 
classified as a slow release formulation. It dif­
fered statistically significantly from the Manucol 
LF tablet in terms of its C^, Cmtx/AUC and 
*1/2 values (Table 1). The pharmacokinetic pro­
file of the Manugel GHB tablet is very similar to 
that of the Manucol DM tablet (Fig. 5) although 
the viscosity grade of the former is 75 mPa s and 
that of the latter 250 mPa s. Thus, the similarity 
between these two formulations in the dissolution 
tests (Fig. 1) could also be seen in the in vivo 
studies. 
The Manugel DPB tablet can be classified as 
an extended-release formulation, since its 
value was 43 h (compared to 2.2 h for immediate 
release products) and t1/2 value 4.3 h (1.6 h for 
immediate release products). The aformentioned 
reference values have been determined in a pre­
vious study in our laboratory (Ojantakanen et al., 
1993). The Manugel DPB tablet differed signifi­
cantly from the Manucol LF tablet in all parame­
ters reflecting absorption rate. It also differed 
significantly from the Manugel GHB tablet re­
garding Cmlx/AUC and f 1/2 values (Table 1). If 
the rate parameters (/„„, Cmax, MRT and 
Cmax/AUC) for the Manugel and Manucol tablets 
are compared with those achieved for ibuprofen 
from hard gelatin capsules containing the same 
viscosity grades of sodium alginate (Veski et al., 
1993) we see very similar absorption rates for 
both formulations. 
Fig. 5 demonstrates that the absorption pro­
files are slightly biphasic, however, the initial slow 
phase lasted only for 1 h. This is too short in view 
of the initial aim of the present study. Although 
in the in vitro tests the initial slow release phase 
lasted for 7-8 h (Fig. 1) it was dramatically shorter 
in vivo. In this respect the in vitro/in vivo corre­
lation was poor. One reason might be the fact 
that the in vitro tests were carried out in a 
neutral solution (pH 7.2) wh eas in the in vivo 
situation the tablets were in the acidic milieu of 
the stomach. For example, the dissolution of ver­
apamil from Manugel DMP based matrix tablets 
has been observed to be pH-dependent: the lower 
the pH the faster the dissolution rate (Timmins et 
al., 1992). In their studies concerning theo­
phylline alginate tablets, Fu Lu et al. (1991) con­
cluded that the dissolution rate of drug was faster 
in acidic media. 
With the Manugel DPB tablets, peak concen­
trations of ibuprofen (f1/21.5-2 h) were obtained 
at 3-6 h (mean 43 h). It can therefore be as­
sumed that another drug with a much longer 
elimination half-life would give Cmax values later 
on, e.g., at about 6 h, which was the main objec­
tive of our study. 
It can be concluded that, with sodium algi­
nates of different chemical structures or viscosity 
grades, it is possible to prepare press-coated 
ibuprofen tablets from which the absorption rate 
Т. Sirkiä et aL/International Journal of Pharmaceutics 00 (1994) 000-000 9 
can be controlled over a fairly wide range from a 
nearly immediate release formulation via slow 
release formulations to an extended-release for­
mulation. 
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SUMMARY 
In the study described here hard gelatin capsules containing pseudoephedrine 
hydrochloride and different grades of sodium alginate were prepared to obtain 
prolonged-release formulations. Evaluation was carried out by means of dissolution 
studies at three pH levels, 1.2, 4.4 and 7.2. Penetration of the dissolution medium 
into the capsule was followed by means of photographs. Bioavailabilities of the 
products were tested in man. At pH 1.2 there was no difference between the 
formulations. At pH 7.2 release rates correlated with viscosity grade of sodium 
alginate. The drug release mechanism could be explained on the basis of the 
photographs. The bioavailability tests confirmed that capsules containing high 
viscosity grades of alginate led to slow release formulations (t^ at 6.5 h) without 
any loss of amount of drug absorbed. It was concluded that the pseudoephedrine 
formulations, which are very simple to make, may be worth consideration in drug 
therapy. 
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Introduction 
Sodium alginates are polysaccharides. They are structurally linear copolymers 
that contain two types of sugar residue: D-mannuronate (M) and L-guluronate (G). 
They occur in alginate molecules in three types of sequence: poly-M, poly-G and 
poly-MG (McDowell, 1986). Sodium alginates are nontoxic. They are widely used 
in the food industry. They have also been extensively studied as additives to solid 
and liquid drug products for peroral administration (Stockwell et al., 1986; Zatz 
and Woodford, 1987; Fu Lu et al., 1991; Timmins et al., 1992; Ojantakanen et al., 
1993). 
Among the many manufacturers of sodium alginates Kelco Ltd is well known. It 
markets two series of alginates under the trade names Manugel™, which is rich in 
guluronic acid, and Manucol™, which is rich in mannuronic acid. We have studied 
the effects of 14 grades of sodium alginate on dissolution rates of ibuprofen from 
hard gelatin capsules (Veski and Marvola, 1993). At pH 7.2, dissolution rates of 
each formulation containing sodium alginate as a diluent followed at pH 7.2 zero-
order kinetics and varied from 5.8 to 58.8% h"1, depending mainly on relative 
amounts and the viscosity grade of alginate used. 
Results of bioavailability studies in man correlated well with in vitro results, and 
showed that it is possible using different grades of sodium alginate to prepare 
ibuprofen capsules from which absorption rates can be controlled over a fairly 
wide range, from slow release to extended-release formulations, without any 
decline in amount of drug absorbed (Veski et al., 1993). In this study the terms 
"slow release" and "extended-release" have been used to discriminate prolonged-
release products to two subgroups as recommended by EC health authorities. Slow 
release products have higher t^ and lower CmM values than the corresponding 
immediate-release product, but in half-lives of the elimination phase there is no 
difference. Between extended-release products and immediate-release products it 
is a marked difference also in the elimination half-life. It is longer for an 
extended-release preparation. The model drug used in these studies was only 
sparingly water-soluble. With a drug that is highly soluble in water, it is possible 
that hard gelatin capsules containing sodium alginate as a diluent would behave 
differently. The effect of low pH on drug release rate could also not be evaluated 
using formulations containing a weak acid as the model drug. 
In the study reported here, the model drug was pseudoephedrine hydrochloride. 
It is highly water-soluble and its aqueous solubility does not depend markedly on 
pH level in the physiological range. Pseudoephedrine is a stereoisomer of 
ephedrine but has fewer central nervous system effects. It is used as a 
decongestant. It is readily absorbed from the gastrointestinal tract It is largely 
excreted unchanged in the urine, with an elimination half-life of 5 to 8 h 
(Kuntzman et al., 1971; Yacobi et al., 1980; Lin et al., 1985). 
The primary aim of the study reported here was to study the effect of pH of the 
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dissolution medium on release rate of pseudoephedrine hydrochloride from hard 
gelatin capsule formulations containing four grades of sodium alginate. Secondarily 
penetration of the dissolution medium into the capsule was studied and an attempt 
was made to discover the mechanism by which the formulation acts as a modified-
release preparation. Finally the bioavailabilities of the formulations in healthy 
volunteers were evaluated. 
Materials and Methods 
Capsule formulations 
Size 0 hard gelatin capsules (Posiloc™, Elanco) were used for all formulations. 
The amount of pseudoephedrine hydrochloride (Knoll AG) per capsule was 100 
mg. Four grades of sodium alginate (Kelco Ltd) were used as diluent. The trade 
names and viscosities (at 25°C) of 1% (w/w) aqueous solutions of these sodium 
alginates were: Manugel DPB (500 mPa-s), Manugel GHB (75 mPa-s), Manucol 
DM (250 mPa-s) and Manucol LD (9 mPa-s). The particle size of all of the 
sodium alginates was as given by the manufacturer <355 jam. 
The amounts of drug needed were weighed in graduated cylinders and diluent 
added to produce sufficient material for 25 capsules (17 ml). Amounts of sodium 
alginate per capsule were: Manugel DPB 431 mg, Manugel GHB 489 mg, 
Manucol DM 513 mg and Manucol LD 513 mg. The powders were mixed 
manually, and capsules were filled using a Feton apparatus. The reference capsule 
in the bioavailability study contained 100 mg of pseudoephedrine hydrochloride 
without additive. 
Drug dissolution 
Dissolution of pseudoephedrine hydrochloride from capsules was determined 
using the USP rotating basket method. Solvents with three pH values were used, 
namely (1) pH 1.2 (0.1 mol/1 hydrochloric acid), (2) pH 4.4 (phosphate buffer 
containing 6.81 g of KH2P04 in one litre of water) and (3) pH 7.2 (phosphate 
buffer containing 6.81 g of KH2P04 and 1.39 g of NaOH in one litre of water). 
The volume of dissolution medium was 900 ml and temperature 37 °C. The speed 
of rotation was 150 min"1. Samples were taken manually. Drug concentrations were 
determined using the HPLC method described in "Plasma assay (Dowse et al. 
1983). The volume of sample administered to the injector was 10 pi. No extraction 
of samples was needed. Goodness of fit of dissolution curves to first-order and 
square-root-of-time equations were tested using Minsq software (Micromath). 
Penetration of dissolution medium into capsules 
The test was analogous to the ordinary dissolution test but the dissolution 
medium contained 0.1% fuchsin (E. Merck), which gave the solution a red colour. 
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At predetermined times, capsules were removed from the dissolution apparatus and 
cut in two. Penetration of the coloured solution was evaluated by visual inspection 
and photography. 
Bioavailability study 
Two groups of eight healthy volunteers (four women and four men in both 
groups) participated in randomized crossover single-dose studies. These were 
carried out in accordance with the recommendations of the Declaration of Helsinki 
(World Medical Assembly 1975) as revised in Tokyo. The ages of the volunteers 
ranged from 19 to 24 years, their weights from 45 to 84 kg. All were nonsmokers. 
None took any drug during the study or one week before it. One week prior to the 
study, participants underwent physical examination, routine laboratory tests and 
ECG examination. The study protocol had been approved by the Ethical 
Committee of the University of Tartu. 
One capsule containing 100 mg of pseudoephedrine hydrochloride was 
administered with 200 ml of water following overnight fasting for at least 10 
hours. A standard lunch was provided four hours after drug administration. The 
first group received reference capsules and capsules containing Manugel DPB, the 
second group capsules containing Manucols. The wash-out period between 
formulations was one week. 
Blood samples of 10 ml were collected from a forearm vein into heparinized 
tubes just prior to drug administration, and 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours 
thereafter. Plasma was separated approximately 30 min after collection by 
centrifugation (3000 g for 10 min), and frozen at -20 °C until analyzed. 
Plasma assay 
Pseudoephedrine plasma concentrations were determined by high-performance 
liquid chromatography (HPLC), using a modified version of the method of Dowse 
et al. (1983). One millilitre of plasma, 50 pi of a saturated solution of sodium 
carbonate and 100 pi of 2 M sodium hydroxide solution were vortexed for 15 s. 
Four millilitres of diethylether were added and the tube was vortexed for 1 min 
and centrifuged for 5 min. Two millilitres of ether extract were transferred to a 
centrifuge tube containing 100 pi of 5% acetic acid. The mixture was vortexed for 
1 min and centrifuged for 5 min. The ether layer was reduced and the water layer 
transferred to a clean tube, from which 50 pi were taken for determination of drug 
levels. Each plasma sample was analyzed in triplicate. Mean values were used. 
The system was equipped with a Waters Model 501 piston pump, a Waters 
Model 717 Intelligent Sample Processor, a Waters Model 486 Turnable 
Absorbance Detector operating at 220 nm and a Waters Model 820 Maxima 
Workstation. Sample separation was carried out on a pBondapak C18 reverse-phase 
column (3.9 X 300 mm). The guard column used was a pBondapak C18. 
The mobile phase was prepared by mixing acetonitrile (200 ml) with 0.005 M 
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solution of sodium- 1-heptanesulfonate in water (800 ml) and adding 2 ml of 1 M 
hydrochloric acid. The flow rate was 1.3 ml min"1. All chemicals were analytical 
or HPLC grade. 
The standard curve was found to be linear over the concentration range 50-1000 
ng ml1 and passed close to the origin. The linear coefficient of determination was 
0.993 or better. Accuracy and precision of the method were investigated as 
recommended by Shah et al. (1992), by analyzing six plasma samples of 
pseudoephedrine concentrations of 50 and 500 ngml"1. Mean values were 45.4 
ngml"1 (CV 18.3%) and 484 ngml"1 (CV 2.7%). The limit of quantitation was 
estimated to be 50 ngml"1. No interfering peaks were observed in the plasma 
blanks. 
Pharmacokinetic parameters 
The pharmacokinetic parameters assessed using the Siphar™ program (Simed) 
were: maximum plasma concentration (Cmix), time to peak concentration (t^, area 
under the concentration-time curve from time 0 to infinity (AUC), elimination half-
life (t^ and mean residence time (MRT). Cmax and values were used as 
measured. AUC and MRT values were calculated by the trapezoidal method, 
without logarithmic transformation. The ratio CmM/AUC was also calculated. 
Statistical analyses were carried out using Student's t-test or Student's paired t-test. 
Values of ^ were analyzed using the nonparametric tests of Wilcoxon and Mann-
Whitney. 
Results and Discussion 
Dissolution studies 
When the hard gelatin capsule contained only 100 mg of pseudoephedrine 
hydrochloride dissolution of the drug was complete in 15 min, regardless of the pH 
of the dissolution medium. Fig. 1 shows the effect of pH on dissolution of 
pseudoephedrine hydrochloride from the four formulations that also contained 
sodium alginate. At pH 1.2, which should mimic in vivo conditions in the 
stomach, there were no differences between the four formulations. At higher pH 
values, the capsule containing the lowest viscosity grade alginate, Manucol LD, 
differed markedly from the others. The differences between the other three 
alginates were minimal, especially at pH 7.2. 
When the capsules'contained Manucol DM, Manugel GHB or Manugel DPB, 
release rate of pseudoephedrine hydrochloride was highest at pH 1.2 and lowest at 
pH 4.4, except for Manugel DPB at pH 7.2. Capsules containing the lowest 
viscosity grade alginate (Manucol LD) differed markedly in their behaviour. 
Slowest drug release was obtained at pH 1.2 and highest at pH 7.2. 
In most cases, the release profiles of pseudoephedrine hydrochloride (Fig. 1) best 
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Fig. 1. Dissolution of pseudoephedrine hydrochloride from hard gelatin capsules 
containing different grades of sodium alginate as diluent: T = Manucol LD, v = 
Manucol DM, + = Manugel GHB, • = Manugel DPB. pH of dissolution medium 
was 1,2 (top), 4.4 (middle) or 7.2 (bottom), means of six parallel tests. 
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fitted first-order kinetics. The only exceptions were Manucol LD capsules at pH 
4.4 and 7.2., where the best model was square-root-of-time kinetics. In this respect, 
the results in this study differ from our previous results with ibuprofen as model 
drug (Veski and Marvola 1993). In our earlier study the only dissolution pH used 
was 7.2, because of the solubility of the drug. In that study the drug-release profile 
followed zero-order kinetic, regardless of the grade of sodium alginate used in the 
capsules. The difference in kinetic profiles can be explained on the basis of 
aqueous solubility of the drugs. Overall release rates for ibuprofen were lower than 
those obtained for pseudoephedrine hydrochloride. In addition, release rate of 
ibuprofen was more readily controllable using different grades of sodium alginate. 
The results reported here only partially correspond to those reported in the 
literature. Stockwell et al. (1986) reported that a cationic drug (chlorpheniramine 
maleate) had a slower release rate from alginate matrices than an anionic drug 
(sodium salicylate). In our study, an anionic drug (ibuprofen) was used as such, 
not as a water-soluble salt In addition, unlike the matrix capsules of Stockwell et 
al., our capsule formulations did not contain calcium phosphate or sodium 
bicarbonate. These affect the gelation properties of alginate and the pH of the 
matrix. As far as in vitro results are concerned, the conclusion from our experience 
is that a simple capsule formulation, containing only the drug and sodium alginate, 
is better with drugs that are only sparingly soluble in water, e.g. weak acids, than 
with highly water-soluble drugs, e.g. hydrochloride salts of basic drugs. 
Timmins et al. (1992) prepared sodium alginate matrix tablets containing 
verapamil hydrochloride. They found that release rates were partially independent 
of the pH of the dissolution medium. If matrices were prepared from sodium 
alginate rich in mannuronic acid (e.g. Manucol DMF) dissolution pH (1.2 or 7.4), 
had no marked effect on dissolution rate. In contrast, if the alginate used was rich 
in guluronic acid (e.g. Manugel DMP) reduction in pH led to a significantly higher 
release rates for verapamil hydrochloride. Our results indicate pH-dependent 
dissolution of pseudoephedrine hydrochloride for all four grades of sodium alginate 
studied. With Manucol DM, Manugel GHB and Manugel DPB, the dissolution rate 
was highest at pH 1.2. With Manucol LD it was lowest at the same pH. 
Penetration studies 
To obtained more information on the formulation, a dye (fuchsin) was added to 
dissolution media. At various times a capsule was removed, cut in two, and 
photographed (Fig. 2). The pH of the solution was 1.2 and the capsules contained 
Manugel DPB as additive. 
At 30 min three layers were visible. The outer layer was tight and fairly hard. 
The second layer was gelatinous and smooth. The intensity of red colour in this 
layer was stronger than that in the outer layer. The core of the capsule was dry. At 
1 to 3 hours all three layers were clearly evident The thickness of the outer layer 
increased more rapidly than that of the second layer. The photograph at 4 h was 
8 
30 min 
Fig. 2. Photographs showing penetration of the coloured dissolution medium into 
pseudoephedrine hydrochloride capsules containing Manugel DPB as diluent The 
figures show the times when the capsules were removed from the dissolution 
equipment. 
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the last in which dry powder was visible in the core. At 6 h the gelatinous part had 
almost totally disappeared. The total volume of the formulation did not increase, 
i.e., there was no marked swelling of sodium alginate. 
It is obvious that hydrochloric acid reacts with sodium alginate, and that än outer 
layer is formed when colloidal alginic acid precipitates. It is possible that the 
gelatin shell also plays a role in the commencement of formation of an outer layer. 
When dissolution medium penetrates the capsule, hydrogen ions are exchanged for 
sodium ions, and the dissolution medium declines in acidity. The second gelatinous 
layer is therefore formed when only slightly acidic or almost neutral solution 
moistens the sodium alginate. This explains why there was no difference in 
dissolution curves between formulations at pH 1.2 (Fig.l). In all formulations, 
alginic acid precipitated and formed the tight outer layer that acted as a rate-
limiting layer in relation to diffusion of pseudoephedrine hydrochloride. 
As the pH of the dissolution medium increased (4.4 or 7.2) no precipitation of 
alginic acid happened. The outer layer consisted only of sodium alginate gel and 
its tightness depended on viscosity grade and chemical nature of the sodium 
alginate used. 
Why did Manucol LD behave differently from the other three grades of sodium 
alginate? The viscosity grade of Manucol LD is very low (9 mPa-s). The gel 
formed from it at pH 4.4 or 7.2 creates only a very weak barrier to diffusion of the 
drug. When a dissolution test is carried out at pH 1.2, colloidal alginic acid creates 
a tight outer layer that forms a better barrier than the low-viscosity sodium alginate 
gels formed at the higher pH's. 
Bioavailability studies 
Fig. 3 and 4 show mean curves for the two bioavailability studies. The 
corresponding individual curves are shown in Fig. 5. Table 1 shows calculated 
pharmacokinetic parameters for each formulation. Results of statistical analyses are 
given in Table 2. There were no statistically significant (p > 0.05) differences in 
the extent of bioavailability (AUC values) between the four formulations. When 
the capsules containing sodium alginate were compared with the reference capsule, 
significant differences were found in the pharmacokinetic parameters describing 
the rate of bioavailability (t^, MRT and CmM/AUC). 
When the lowest viscosity grade alginate (Manucol LD) was used, prolongation 
of the absorption phase was relative low, e.g. a change in mean value from 
2.88 h (reference) to 4.00 h. There were no significant differences in MRT and 
C^/AUC values (Table 1). When Manucol DM or Manugel DPB was used, 
absorption of pseudoephedrine was more obviously retarded: t,,,,, for both 
formulations was 6.5 h. MRT and C^/AUC values also differed statistically 
significantly from those for the reference capsule (Table 2). As far as apparent 
elimination half-lives (t^) were concerned, there were no differences between the 
reference capsule and the capsules containing sodium alginates. The conclusion 
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Fig. 3. Mean plasma concentration curves of pseudoephedrine after administration 
of 100 mg of pseudoephedrine hydrochloride in capsules containing the drug alone 
(•) or in capsules containing Manugel DPB as diluent (*), means ± S.E.M, n = 8. 
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Fig. 4. Mean plasma concentration curves of pseudoephedrine after administration 
of 100 mg of pseudoephedrine hydrochloride in capsules containing Manucol LD 
(*) or Manucol DM (D) as diluent, means ± S.E.M., n = 8. 
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Fig. 5. Individual plasma concentrations of pseudoephedrine after administration 
of 100 mg of pseudoephedrine hydrochloride in different capsule formulations. 
Formulations: A = capsule containing drug alone, В = capsule containing Manugel 
DPB as diluent, С = capsule containing Manucol DM as diluent, and D = capsule 
containing Manucol LD as diluent 
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Table I. Pharmacokinetic parameters of pseudoephedrine in hard gelatin capsules containing 
different grades of sodium alginate as diluent. Reference capsules contained only the drug. 
Single peroral dose: 100 mg of pseudoephedrine hydrochloride (means ± S.D, n = 8). 
Parameter Reference 
Diluent 
Manugel DPB Manucol DM Manucol LD 
AUC ngml ' h 
Cmax ng-ml'1 
tm« h 
t* h 
MRT h 
Cmax/AUC h1 
5465±2082 
466±131 
2.88±0.64 
5.98±0.94 
9.56±1.27 
0.088±0.013 
5742±1668 
392±104 
6.50±1.77 
6.04±1.11 
11.8±1.41 
0.069±0.010 
5121±810 
369±85 
6.50Ю.93 
6.3Ш.83 
11.7±2.45 
0.072±0.011 
4428±1607 
368±112 
4.00±0.93 
4.81±0.57 
9.18±0.79 
0.087±0.016 
Table П. Statistical analysis of calculated pharmacokinetic parameters for pseudoephedrine 
capsules containing different grades of sodium alginate as diluent. Reference values are 
parameters obtained for capsules containing the drug alone. Statistical methods: Student's paired 
t-test for Manugel DPB, Student's unpaired t-test for Manucol DM and Manucol LD. 
Diluent 
Parameter 
Manugel DPB Manucol DM Manucol LD 
AUC NS NS NS 
c„„ NS NS NS 
^mex ** ** * 
NS NS NS 
MRT * * NS 
Cmu/AUC * * NS 
* = p<0.05, ** = pcO.Ol, NS = not significant 
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from the results of in vivo studies is therefore that formulations containing 
Manucol DM or Manugel DPB can be classified as slow release preparations. 
When the bioavailabilities of similar capsules containing ibuprofen instead of 
pseudoephedrine hydrochloride were studied the conclusion was that formulations 
containing Manucol DM or Manugel GHB could be classified as slow release 
preparation but formulation containing Manugel DPB as extended-release 
preparation (Veski and Marvola, 1993). The results of in vivo studies therefore 
confirmed the conclusion from results of in vitro tests that capsule formulations 
containing sodium alginate are better in relation to drugs that are sparingly soluble 
in water than in relation to highly water-soluble drugs. 
The interindividual variation evident in Fig. 5 is normal for such modified-release 
formulations, especially if variation in weights of volunteers (45 to 84 kg) are 
taken into account. AUC values with slow release formulations in the study 
reported here (5742 and 5121 ngml ! h) are higher than the corresponding value 
for a commercial modified-release product (4483 ngml ' h), although the 
pseudoephedrine hydrochloride dose was lower: 100 mg versus 120 mg (Wecker 
et al., 1987). In addition, t,,,« occurred at 6.5 h in the study reported here. With the 
commercial preparation t^ occurred at 4.5 h. The pseudoephedrine formulations 
described here could therefore be worth considering in clinical situations. 
Comparison of in vitro and in vivo results 
Results of in vitro studies in acid environments, e.g. at pH 1.2, are often thought 
to allow optimum prediction of the in vivo fate of a drug product. In the study 
reported here, there were no differences between formulations at pH 1.2 (Fig. 1). 
In vivo, however, differences between formulations were evident (Figs. 3 and 4, 
Table 1). 
It is possible that the capsules remained for 0.5 to 2 h in the stomachs of 
volunteers. During this time, an outer layer consisting of precipitated alginic acid 
is formed. A similar layer is also seen in vitro studies (Fig. 2). The alginic acid 
layer, which is not hydrophillic does not favour adherence of the formulation to 
the gastric mucosa for a long time. Under fasting conditions, movements of the 
migrating myoelectric complex ("housekeeper" wave), appearing approximately 
every second hour (Minami and McCallum, 1984), therefore sweep the capsule to 
the small intestine. The solution subsequently penetrating into the capsule is no 
longer acid. The rest of the sodium alginate in the core forms a gel. Its tightness 
depends on the viscosity grade of the polymer. This is why the in vivo absorption 
rate correlates with the viscosity grade of sodium alginate although no differences 
were seen in dissolution studies at pH 1.2. 
26 
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